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ABSTRACT 
 
Objectives: Felodipine is used as an antihypertensive and antianginal drug, widely 
used orally in the treatment of hypertension. The model drug belongs to BCS class II 
and undergoes extensive first-pass metabolism with a bioavailability of only about 
15%. Hence this work was planned to improve the oral bioavailability of felodipine 
by increasing its solubility and dissolution characteristics through the solid dispersion 
technique using polyethylene glycol (PEG 4000) and hydroxypropyl cellulose (HPC) 
as carriers. 
Methods: Solid binary systems of felodipine were prepared with PEG  4000 by 
solvent deposition (SD) and kneading method (KM) at different drug:carrier ratios of 
1:1, 1:3 and 1:5. Then ternary systems were prepared with the addition of different 
concentrations of HPC to felodipine-PEG  4000 binary systems to investigate the 
effect of hydrophilic polymer on the solubility and dissolution rate of the felodipine. 
Solid binary and ternary systems were characterized by drug content, FT-IR, XRD 
and in vitro dissolution test using USP dissolution test apparatus Type II (paddle 
method) in dissolution medium of 0.1N HCl. The in vitro dissolution results of all 
preparations were computed by using dissolution software PCP DISSO V3. 
Results: All prepared solid binary and ternary systems were found to be fine and free 
flowing.  Low  standard  deviation  (SD)  values   (i.e.,  <   1)  indicated  uniform  drug  
distribution  in  all  prepared  batches.  FT-IR  studies  indicated  the  possibility  of 
intermolecular  hydrogen  bonding  between  amide  group  of  the  felodipine  and 
hydroxyl group of the PEG 4000. The XRD results indicated the significant reduction 
in felodipine crystallinity in the solid binary and ternary systems. The DE30 and DE60 
values of the solid binary systems prepared by the kneading and solvent deposition 
methods were relatively high (P < 0.01) compared to the values rom the physical  
mixtures (PMs) and felodipine alone. The overall the rank order of improvement in 
dissolution properties of felodipine with different methods in all ratios was KM > SD > 
PMs > felodipine. All ternary systems exhibited a significant increase in dissolution 
 ii 
 
rate with respect to the PMs and the reference drug. The value of T50 and MDT of all 
solid binary and ternary systems were lower than felodipine alone. It was noted that 
the dissolution was progressively increased with increasing concentration of carriers 
in both binary and ternary systems. The release pattern in felodipine, PMs and all 
solid binary and ternary systems showed best  fit  into first-order with highest   ‘r’  
(correlation coefficient) values. 
Conclusions: Solid binary and ternary systems of felodipine prepared with PEG 4000 
and HPC were found to be effective in improving the solubility and dissolution rate of 
the model drug. Enhanced dissolution of felodipine from solid binary and ternary 
systems could be mainly attributed to the particle size reduction as well as decreased 
drug crystallinity (demonstrated by XRD).   The study revealed that optimum ratios of 
hydrophilic carriers ensure a prompt and complete dissolution of felodipine from solid 
binary and ternary systems that are used in oral pharmaceutical formulations. 
Keywords: Felodipine, polyethylene glycol (PEG 4000) and hydroxypropyl cellulose 
(HPC), solid binary and ternary systems. 
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INTRODUCTION 
1.1  Drug solubility 
 Solubility enhancement of poorly water-soluble drugs is a crucial issue to 
improve their solubility and bioavailability. In recent years, due to application of 
combinational chemistry and high throughput screening during drug discovery, a 
majority of new drug candidates exhibits poor aqueous solubility. Such compounds 
are very challenging for formulation scientists in developing bioavailable dosage 
forms. Poorly water soluble compound has classically been defined as one 
dissolving in less than  1 part per  10000 part of water1. A poorly water soluble drug, 
more recently, has been defined in general terms to require more time to dissolve in 
the gastrointestinal fluid than it takes to be absorbed in the gastrointestinal tract2. 
Thus a greater understanding of dissolution and absorption behaviours of drugs with 
low aqueous solubility is required to successfully formulate them into bioavailable 
drug products.  
 Consideration of the modified Noyes-Whitney equation provides some 
hints as to how the dissolution rate of poorly soluble compounds might be improved 
to minimize the limitations to oral bioavailability.  
s bAD(C - C )dc =
dt hV  
Where,  dc/dt =  Rate of dissolution  
 A = Surface area available for dissolution   
 D  =  Diffusion coefficient of the compound 2  
 Cs  =   Solubility of the compound in the dissolution medium   
 Cb  =   Concentration of drug in the medium at time  
 h   =    Thickness  of  the  diffusion  boundary  layer  adjacent  to  surface  of  
the dissolving compound  
 V  =  Volume of dissolution media  
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 The main possibilities for improving dissolution according to this analysis 
are to increase the surface area available for dissolution by decreasing the particle 
size  of  the  solid  compound and/or  by  optimizing  the  wetting  characteristics  of  the  
compound to decrease the boundary layer thickness, to ensure sink conditions for 
dissolution and last but definitely not least, to improve the apparent solubility of the 
drug under physiologically relevant conditions.  
1.2  Various approaches to improve the solubility3  
I.  Physical modifications 
A.  Particle size: Micronization and Nanosuspensions  
B.  Modifications of the crystal habit:  Polymorphs and 
Pseudopolymorphs  
(including solvates)  
C.  Complexation/solubilization: Use of surfactants and  cyclodextrins  
D.  Drug dispersion in carriers: Eutectic mixtures, solid dispersions 
(non- 
molecular) and solid solutions  
II.  Chemical modification 
 This includes soluble prodrugs, salt formation and covalent polymer drug 
conjugates.  
1.3 Solid dispersions (SDs)  
 The  formulation  of  hydrophobic  drugs  as  SDs  is  a  significant  area  of  
research aimed at improving their dissolution and bioavailability. Solid dispersions 
consisting of two components in the solid state are referred to as binary systems. The 
two components are a water-soluble carrier and a hydrophobic drug dispersed in the 
carrier substance4. Solid dispersion method of improving the dissolution rate of 
poorly soluble drugs was first proposed sekiguchi K and Obi N5. It is a unique 
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approach  to  present   a   poorly   soluble   drug   in   an   extremely   fine   state   of   
subdivision  in gastrointestinal fluids. The term  ‘solid dispersion’ has been utilized 
to describe a family of dosage forms whereby one or more active ingredient is 
dispersed in a biologically inert matrix, usually with a view to enhancing oral 
bioavailability.  
 Chiou and Riegelman6 defined the term solid dispersion as ‘the dispersion 
of one or more active ingredients in an inert carrier matrix at solid-state 
prepared by the melting  (fusion), solvent or melting-solvent method’. While 
Corrigan7 suggested the definition as ‘product formed by converting a fluid drug-
carrier combination to the solid state’  
 Several insoluble drugs have been shown to improve their dissolution 
character when incorporated into solid dispersion. SDs releases the drug through 
different mechanisms, and the rate of release of drug to the surrounding fluid is 
mainly  dependent  on  the  type  of  solid  dispersion  formed8,9. Solid dispersion 
technique has been widely employed to improve the dissolution rate, solubility and 
oral adsorption of poorly water soluble drugs10,11.  
1.3.1  Classification of SDs12 
 On the basis of release mechanisms and molecular arrangement in the 
matrix, SDs are distinguished into following types,  
Simple eutectic mixture: Eutectic mixture is prepared by rapid solidification of 
fused melts of two components that show a complete liquid miscibility with 
negligible solid-solid solubility. It involves loose atomic or molecular interaction 
and not on the formation of chemical bond. When the eutectic mixture is exposed to 
gastrointestinal fluids, both the poorly soluble drug and the carrier may 
simultaneously crystallize out as  a  very  small  particles  resulting  in  increased  
the  surface  area  and  improved dissolution and absorption of drug.  
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Solid solutions: A solid solution represents a homogenous one phase system, where 
the solid solution is dissolved in a solid solvent and the two components crystallize 
together. The solid solution achieves faster dissolution than a eutectic mixture 
because the drug particles in a solid solution are reduced to molecular size and 
dissolution of the drug takes place in the solid state prior to the exposure to the 
liquid medium. According to the extent of miscibility between the two components 
or the crystalline structure of the solid solution, it is further classified into 
continuous, discontinuous, substitutional and interstitial solid solution.  
Continuous solid solution: The two components in this system are miscible in all 
proportions. The fast dissolution properties of such system may be attributed to the 
presence of small amount of solute carrier in the crystalline lattice of the poorly 
soluble drug.  
Discontinuous solid solution: In this system, there is a limited solubility of a solute 
in solid solvents. Each component is capable of dissolving the other component to a 
certain degree above the eutectic temperature.  
Substitutional solid solution: In this system, the solute molecules substitutes for the 
solvent molecules in the crystal lattice of the solid solvent. It can form a continuous 
or discontinuous solid solution.  
Interstitial solid solution: In this system, solute molecules occupy the interstitial  
space of the solvent lattice. Water soluble carrier with higher molecular weight such  
as PEG 4000, PEG 6000 and PEG 12000 were employed for this purpose. Several  
scientists have reported faster dissolution of drugs from solid dispersion based on 
this  
method.  
Glass solution: It is a homogenous glassy system in which a solute dissolves on 
glassy  solvent  results  in  increased  dissolution  and  absorption  of  the  drug.  It  
is characterized by a transparency and brittleness below the glass forming 
temperature. Glass solution is a metastable and strength of the chemical bonding is 
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much less as compared to solid solution. Therefore, the release of the drug was 
found to be faster than solid solution.  
Amorphous  precipitations  in  crystalline  carrier:  Amorphous  form  of  a  drug 
produces faster dissolution rate. The drug may precipitate out in an amorphous form 
in a crystalline carrier from solid dispersions prepared by melting or solvent method. 
A strong interaction between the drug and carrier resulting in the formation of 
channels  with  in  the  matrix  seems  to  be  a  possible  mechanism  for  improved 
dissolution of drug.  
Compound or complex formation: The formation of complex between the drug 
and the carrier may either decrease or increase the dissolution and absorption rate of 
drug. The formation of soluble complex with low association constant resulted in 
increased rate of dissolution and absorption.  
1.3.2 Preparation techniques of SDs 13, 14  
Solvent evaporation method: In this method, physical mixture of two components 
(drug and carrier) are dissolved in a common solvent and followed by the 
evaporation of solvent. The advantages of this method are low temperature 
requirement for the preparation of dispersion and thermal decomposition of drugs 
and carriers can be prevented. The higher cost of production, incomplete removal of 
solvent, adverse effects of solvent on the chemical stability of the drug and selection 
of common solvent are the drawbacks of this method.  
Melting method (Fusion method): The physical mixture of drug and water soluble 
carrier was heated to melt and the molten mixture was then cold and solidified mass 
was crushed, pulverized and sieved. The melting point of a binary system depends 
on its composition and proper manipulation of drug carrier ratios. Decomposition 
should be avoided due to fusion time and rate of cooling.  
Kneading method: The physical mixture of drug and carrier were triturated using  
small quantity of organic solvent and water mixture, usually alcohol and water  
(1:1w/w). The slurry is kneaded for 45 minutes to 1 h and dried at 45oC. The dried  
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mass is pulverized and sieved through sieve no 60 and the fraction was collected. 
The advantages of this method are low temperature requirement for solid dispersion 
preparation, less usage of organic solvent11 and avoidance of thermal degradation of 
the drug.  
Melting solvent method: This method involves dissolving the drug in a suitable 
solvent and incorporation of the solution directly into the molten carrier. This 
method possesses the advantages of both solvent and melting methods.  
Spray  drying:   Spray   drying   technique   finds   more   important   utility   in   the  
pharmaceutical industry due to rapid drying and specific physical characters such as 
particle size and shape of the product. It consists of dissolving or suspending the 
drug and carrier, then spraying it into a stream of heated air flow to remove the 
solvent. It is a cost effective process as compared to that of freeze drying resulting in 
the production of fine solid particles. The operation conditions and design of the 
drier depends upon the drying characteristics of the product and powder 
specifications. Spray drying technique is useful to obtain spherical particles with 
narrow distribution.  
Lyophillization technique: This technique is an alternative to solvent evaporation 
method. Here the drug and carrier are dissolved in common solvent, frozen and 
sublimed to obtain lyophilized molecular dispersion.  
Melt agglomeration process: This technique is used to prepare solid dispersion  
where a binder acts as a carrier. The solid dispersion is prepared by heating binder,  
drug and excipient to a temperature above the melting point or spraying the 
dispersion of drug in the molten binder on the heated excipients using a high shear 
mixer. The effect of binder type, method preparation and particle size are the critical 
factors influencing the solid dispersion preparation by this method. These 
parameters results in  various  dissolution  rates,  mechanism  of  agglomerate  
formation  and  growth, agglomerate size and distribution.  
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Supercritical fluid methods: Supercritical fluid methods are mostly applied with  
carbon dioxide (CO2), which is used as either a solvent for drug and matrix or as an  
anti-solvent. This technique consists of dissolving the drug and the carrier in a  
common solvent that is introduced into a particle formation vessel through a nozzle,  
simultaneously  with  CO2.  When  the  solution  is  sprayed,  the  solvent  is  rapidly  
extracted by the SCF, resulting in the precipitation of solid dispersion particles on 
the walls and bottom of the vessel. This technique does not require the use of 
organic  solvent   and   since   CO2  is  considered  environmentally  friendly,  this  
technique  is referred  to  as ‘solvent  free’.  This  technique  is  known  as  Rapid  
Expansion   of  Supercritical  Solution   (RESS).  However,  the  application  of  this  
technique is very limited, because the solubility of CO2 of most pharmaceutical 
compounds is very low.  
Co-precipitation method: In this process, a non-solvent is added drop wise to the 
drug and carrier solution under constant stirring. In the course of the non-solvent 
addition, the drug and carrier are co-precipitated to form microparticles. At the end, 
the resulted microparticles suspension is filtered and dried.  
Spin-coated films: This is a new process to prepare SDs by the solvent evaporation  
method, which consists of dissolving drug and carrier in a common solvent that is  
dropped onto a clean substrate highly spinned. Solvent is evaporated during 
spinning. This process is indicated to moisture sensitive drugs since it is performed 
under dry conditions.  
1.3.3 Mechanism  of  drug  release  from  SDs:   
 The  possible  mechanisms  of enhanced dissolution from SDs include one 
or more of the following6 ,  
Reduction in particle size and agglomeration: Reduction in particle size and 
agglomeration increases the exposed surface area of the drug. Size reduction has 
been classically considered to be a result of eutectic or solid solution formation; it is 
worth noting that this mechanism suggests an intrinsic link between solid state 
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structure  and  release.  Similarly  it  has  been  suggested  that  the  presentation  of 
particles  to  the  dissolution  medium  as  physically  separate  entities  may  reduce 
aggregation. In addition, many of the carriers used for SDs may have some wetting 
properties; hence it is reasonable to suggest that improved wetting may lead to 
reduced agglomeration and hence increased surface area.  
Increased solubility or dissolution rate of the drug: Many of the carriers used 
may increase the solubility of the drug. Similarly, the carrier and drug may form a 
soluble complex,  as  established  in  case  of cyclodextrins.  Also,  changes  to  the  
physical properties of the drug such as degree of crystallinity and polymorphic form 
may also be considered under this category.  
Conversion of crystalline drug into amorphous form: Since the amorphous form 
is the highest energy form of a pure compound, it produces faster dissolution.  
1.3.4.  The advantageous properties of SDs15  
 Management of the drug release profile using solid dispersions is achieved 
by manipulation of the carrier and solid dispersion particles properties. Parameters, 
such as carrier molecular weight and composition,  drug  crystallinity  and  particle  
porosity  and  wettability,  when successfully controlled, can produce improvements 
in bioavailability.  
Particles with reduced particle size:   Molecular dispersions, as solid dispersions, 
represent the last state on particle size reduction, and after carrier dissolution the 
drug is molecularly dispersed in the dissolution medium. Solid dispersions apply this 
principle to drug release by creating a mixture of a poorly water soluble drug and 
highly soluble carriers. A high surface area is formed, resulting in an increased 
dissolution rate and, consequently, improved bioavailability.  
Particles with improved wettability: Strong contribution to the enhancement of 
drug solubility is related to the drug wettability improvement in solid dispersions. It 
was observed that even carriers without any surface activity, such as urea improved 
drug wettability. Carriers with surface activity, such as cholic acid and bile salts, 
Introduction  
9 
Department of Pharmaceutics, AVPC 
when used, can significantly increase the wettability properties of drugs. Moreover, 
carriers can influence the drug dissolution profile by direct dissolution or co-solvent 
effects  recently,   the   inclusion   of   surfactants   in   the   third   generation   solid   
dispersions reinforced the importance of this property.  
Particles with higher porosity: Particles in solid dispersions have been found to  
have a higher degree of porosity. The increase in porosity also depends on the carrier  
properties, for instance, solid dispersions containing linear polymers produce larger  
and more porous particles than those containing reticular polymers and, therefore, 
result in a higher dissolution rate. The increased porosity of solid dispersion particles 
also hastens the drug release profile.  
Drugs in amorphous state: Poorly water soluble crystalline drugs, when in the 
amorphous state tend to have higher solubility. The enhancement of drug release can 
usually be achieved using the drug in its amorphous state, because no energy is 
required  to  break  up  the  crystal  lattice  during  the  dissolution  process.  In  solid 
dispersions, drugs are presented as supersaturated solutions after system dissolution, 
and it is speculated that, if drugs precipitate, it is as a metastable polymorphic form 
with higher solubility than the most stable crystal form.  
1.3.5 Methods  of  characterization  of  SDs16  
 The  SDs  can  be  studied  and characterized in two ways as follows,  
In solution state: Solubility studies, Dissolution studies, UV-spectral studies, and 
1H NMR studies.  
In solid state: Microscopic methods including polarization microscopy and 
scanning electron microscopy (SEM), thermo analytical methods which includes 
differential scanning calorimetry (DSC) and hot stage microscopy (HSM), thermo 
gravimetric analysis (TGA), spectroscopic methods i.e., fourier transform infrared 
spectrometry (FTIR) and powder X-ray diffractometry (PXRD).  
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1.3.6  Carriers used for solid dispersions16  
 A large number of different materials have been examined as potential 
carriers to prepare solid dispersions. These are summarized in table1.   All carriers 
differ widely in their physical and chemical properties. The properties of the carrier 
have a major influence on the dissolution characteristics of the dispersed drug. A 
carrier chosen for SDs should be freely water soluble, soluble in a variety of 
solvents, non toxic, chemically, physically and thermally stable, compatible with the 
drug and pharmacologically inert.  
Table1: Various carriers used in SDs 
S.No Nature of carrier Name of the carrier 
1. Sugars Dextrose,   sorbitol,   sucrose,   fructose,  maltose,  
galactose, xylitol, mannitol and lactose. 
2. Acids Citric acid, tartaric acid and succinic acid 
3. Polymorphic 
materials 
Polyvinylpyrrolidone (PVP),  polyethylene  glycols 
(PEG4000,6000),  hydroxyl  propyl  methyl  cellulose 
(HPMC), guargum, xanthan gum, sodium alginate, 
methyl cellulose, pectin,  hydroxylethylcellulose 
(HEC),  hydroxyl  propyl cellulose (HPC) and 
dextrins. 
4. Insoluble or enteric 
polymer 
Hydroxypropylmethylcellulosepthalate,  Eudragit RL, 
Eudragit L100, Eudragit S100, Eudragit RS. 
5. Surfactants Polyethylene stearate, poloxamer 188, tweens and 
spans. 
6. Miscellaneous Nicotinic acid, succinamide, dextrin’s, gelatin, 
polyvinyl alcohol,urea,cyclodextrins etc. 
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2. LITERATURE REVIEW 
 Pawar S et al17 studied the SDs of felodipine with polyvinylpyrrolidone 
(PVP K30) and HPMC K4M prepared by solvent evaporation method. The FTIR 
study revealed no chemical interaction between felodipine and carriers used. The 
XRD and DSC studies confirmed the transformation of crystalline form of 
felodipine into the amorphous form. The in vitro dissolution studies showed that the 
solid dispersion of felodipine:PVP:K30 with the 1:3 ratio enhanced the solubility of 
felodipine.  
 Dong-Han  W  et  al18 studied the SDs of felodipine with HPMC and 
surfactants  by  the  conventional  solvent  evaporation (CSE)  and  supercritical   
anti-solvent precipitation  (SAS) methods. The solid dispersion particles were 
characterized by particle size, zeta potential, SEM, DSC, powder XRD, solubility 
and dissolution studies. The effects of the drug:polymer ratios and surfactants on the 
solubility of felodipine were studied. The SDs from the SAS process showed a high 
dissolution rate of felodipine about 90% within 2 h.  
 Mohamed HG et al19 investigated the effect of different types of carriers on 
in vitro dissolution of meloxicam. Meloxicam SDs were prepared by physical 
mixing,  co-grinding   and   solvent   evaporation   methods   with   PEG  6000.   The   
effect   of   solubilisation  by  sodium  lauryl  sulphate  (SLS)  was  also  studied.  The  
maximum in vitro  dissolution  of  meloxicam,  i.e. 97.45%  in  60  min,  was  
observed  for  SDs containing meloxicam (150 mg), PEG 6000 (350 mg) and SLS 
(75 mg) prepared by solvent evaporation method.  
 Kim EJ et el20 prepared and evaluated felodipine SDs (solvent wetting 
method) in the presence of various carriers. The results of XRD and thermal analysis 
indicated that the drug was in the amorphous state when PVP, HPMC, and 
poloxamer were used as carriers. The dissolution rates of felodipine in PVP, HPMC, 
or poloxamer SDs were much faster than those for the corresponding PMs. 
However, dissolution profiles were found to depend on the carrier used. The 
dissolution rate of felodipine increased slowly for SDs prepared using HPMC, 
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whereas rapid initial dissolution rates were observed for SDs prepared using PVP or 
poloxamer. Increases in dissolution rates were partly dependent on the ratios of 
felodipine to carrier. The results indicated that no significant changes in crystal form 
were  observed  by  XRD  or  thermal  analysis,  and  also  no  significant  changes  in  
dissolution rate were observed when sorbitol and mannitol were used as carriers.  
 Markus V et al21 prepared and investigated solid dispersion systems of four 
poorly  soluble  drugs (EMD  57033,  albendazole,  danazol  and  felodipine)  by 
cogrinding with lactose monohydrate, corn starch, PVP, HPMC and SLS using a jet 
milling technique. A solid state characterization study was done by XRD and DSC. 
The  results  suggested  that  the  cogrinding  with  selected  excipients  would  be  a 
powerful tool to accelerate the dissolution of poorly soluble drugs without 
converting the drug to the amorphous form or changing the particle size.  
 Bosca MT et al22 studied flunarizine SDs prepared with PEG 4000 at 
different ratios. The physicochemical characterizations of SDs were investigated by 
FT-IR, XRD,  DSC  and  solubility  in  equilibrium.  The  FT-IR  results  suggested  
that  no chemical interaction between flunarizine and PEG 4000. The XRD patterns 
confirmed the decrement in crystallinity at certain proportions and DSC indicated 
the formation of eutectic mixture. Equilibrium solubility studies showed that drug 
solubility was enhanced as the polymer content in the samples increased.  
 Moreshwar PP et al23  studied gliclazide and PEG 4000 SDs by melting or 
fusion method. The in vitro dissolution  studies  showed  that  PEG  was  found  to  be  
effective in increasing the dissolution of gliclazide in SDs when compared to pure 
drug. FT-IR, DSC and XRD studies were carried out in order to characterize the 
drug  in  the  PMs  and  SDs.  The  results  indicated  that  dissolution  enhancement  was  
attributed to decreased crystallinity of the drug and also due to the wetting and 
solubilizing effect of the carrier from the gliclazide SDs.  
 Vijaya Kumar SG et al24 prepared solid dispersion systems of meloxicam 
with PEG 6000 by solvent evaporation method. The formulations were characterized 
by solubility studies, DSC, FT-IR and in vitro dissolution rate studies. FT-IR studies 
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indicated the possibility of hydrogen bonding with the polymer. The DSC and 
powder XRD demonstrated the presence of polymer as eutectic (crystalline, 
amorphous or a mixture of both) mixture. The overall results confirmed that SDs of 
meloxicam demonstrated higher drug dissolution rates than PMs and meloxicam 
alone.  
 Sethia S et al25  studied carbamazepine (CBZ) solid dispersions prepared 
by  conventional solvent evaporation versus a supercritical fluid method. The SDs of  
carbamazepine  in  PVP  K30  with  Gelucire   44/14  or  Vitamin  E  TPGS,  NF    
(D-Į-tocopheryl  polyethylene  glycol 1000  succinate)  were  characterized  by  
intrinsic dissolution,   DSC,   powder   XRD   and   FT-IR.   The   CBZ/PVP   K30   
and  CBZ/PVPK30/TPGS SDs showed increased dissolution rate. Thermograms of 
various  SDs did not show the melting peak of CBZ, indicating that CBZ was in 
amorphous  form inside the carrier system. This was further confirmed by XRD studies. 
FT-IR studies showed interaction between CBZ and PVP K30 in solid dispersion.  
 Masoud RJ et al26 prepared SDs of miconazole nitrate  (MN), using three 
different water soluble excipients PEG  6000, PVP-10,000 and urea by fusion or 
coprecipitation from ethanol. A seven-fold increase in the dissolution rate of MN 
was achieved with both PEG and urea, while the dispersion of MN in PVP resulted 
in only two fold enhancement.  
 Venkatesh Kumar K et al27 attempted to improve the solubility and 
dissolution rate of a poorly soluble drug, valsartan by solid dispersion method using 
skimmed milk powder as carrier. Four different formulations were prepared with 
varying  drug:  carrier   ratios   of  1:1,  1:3,  1:5   and   1:9.   The   formulations   were   
characterized  for solubility parameters, drug release studies, phase solubility 
studies, XRD, FT-IR and TLC  analysis.  All  prepared  formulations  showed  
marked  improvement  in  the solubility behavior and improved drug release. 
Formulation containing drug:polymer ratio of 1: 9 showed the best release as 
compared the pure drug. The analytical studies confirmed no interaction between the 
drug and the carrier. It was concluded that skimmed milk powder could be utilized 
as a carrier to improve the solubility of poorly soluble drugs.  
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 Shinde   SS   et   al28  investigated  SDs  of  aceclofenac  prepared  by  
solvent evaporation method and compared the effectiveness of hydrophilic polymer 
such  as  PVP-K30,  HPMC  E-5  and  Aerosil  200.  The  resultant  complexes  were  
evaluated for drug content, FT-IR, XRD and dissolution studies. The present study 
was successfully utilized the solvent evaporation method for preparation of stable, 
amorphous SDs of aceclofenac by encapsulation with hydrophilic carrier with 
adsorbents agent. The results revealed that batch prepared at 1:1:2 ratios of drug: 
PVPK30:aerosil showed maximum release in phosphate buffer of pH 6.8.  
 Arora  SC  et  al29 investigated the cefixime trihydrate solid dispersion 
prepared with urea by solvent evaporation method to increase its solubility and 
dissolution rate.  Physical mixtures and SDs of cefixime trihydrate were prepared by 
using urea as water-soluble carrier in various proportions (1:1, 1:2, 1:3, 1:4, 1:5, 
1:6, 1:7 by weight). The drug release profile was studied and it was found that the 
dissolution rate and the dissolution parameters of the drug from the physical mixture 
as well as solid dispersion were higher than those of the intact drug. FT- IR studies 
revealed no chemical incompatibility between drug and urea.  
 Ahire  BR  et  al30 investigated to improve the solubility of nevirapine by 
solid  dispersion   techniques   using   PVP   K30   as   carrier   by   physical   mixing,   
solvent evaporation and kneading method. The interaction of the nevirapine with 
PVP K30 was evaluated by the FTIR spectroscopy, DSC and XRD. The results from 
the FT-IR and XRD analyses showed that solid dispersion might exist in the 
amorphous  form.  A  DSC   results   showed   that   the   sharp   melting   point   was   
completely  disappeared suggested that the nevirapine was molecularly dispersed in 
an amorphous form. Saturation  solubility  and  dissolution  studies  indicated  that  
dissolution   rate   was  remarkably  increased  in  solid  dispersion  as  compared  to  the  
physical mixture and drug alone.  
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AIM AND OBJECTIVES OF THE STUDY 
Aim of the study  
 In recent years, the number of poorly soluble drug candidates has 
increased tremendously and formulation of such poorly soluble drugs for oral 
delivery presents a great challenge to the formulation scientists. Solubility behaviour 
of a drug is one of the key determinants of its oral bioavailability. Most useful 
remedy to overcome the inherent difficulties associated with the formulation and 
development  of  a  poorly  water   soluble   drug   is   to   enhance   its   solubility.   
Different   approaches   have   been  developed  to  enhance  the  drug  release  and  
dissolution rate of poorly water soluble drugs. Among them, the solid dispersion 
method is the most effective technique to improve the aqueous solubility and the 
dissolution of poorly water soluble drugs. Hence the present study was planned to 
improve the solubility and dissolution rate of felodipine (a poorly soluble drugs) 
through solid dispersion technique.  
Study objectives  
 Felodipine is used as an antihypertensive and antianginal drug, widely 
used orally for the treatment of hypertension. The model drug belongs to BCS class 
II drug (low solubility and high permeability). It undergoes extensive first-pass 
metabolism with a bioavailability of only about  15%. The major drawback in the 
therapeutic application  and  efficacy  of  felodipine  as  oral  dosage  form  is  its  
low  aqueous solubility.  Hence  this  work  was  planned  to  improve  solubility  
and  dissolution characteristics of felodipine using PEG 4000 and HPC as 
hydrophilic carriers through solid dispersion technique.  
Drug and Excipient Profile  
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DRUG PROFILE31-35 
Felodipine:  Felodipine is a dihydropyridine calcium-channel blocker, used alone or 
with an angiotensin-converting enzyme inhibitor to treat hypertension, chronic 
stable angina pectoris and Prinzmetal's variant angina. It lowers blood pressure by 
reducing peripheral vascular resistance through a highly selective action on smooth 
muscle in arteriolar resistance vessels.  
Physicochemical Properties  
 
 
 
 
 
 
Chemical name : (±)-Ethyl methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-
 dimethyl-3,5 pyridinedicarboxylate  
Molecular formula :  C18H19Cl2NO4  
Molecular weight :  384.25  
Category :  Antihypertensive and antianginal drug  
Description :  Slightly yellowish and crystalline powder  
Storage  :  It should be stored in light resistant container in a cool place.  
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Solubility :  It is insoluble in water and freely soluble 
dichloromethane and ethanol  
Experimental Log P : 3.8  
Predicted Log P :  4.36  
Melting point :  142 to145oC  
Pharmacokinetic data  
Oral bioavailability :  15%  
Urinary excretion :  1%  
Plasma protein binding :  99%  
Clearance :  0.8 L/min  
Volume of distribution :  10 L/Kg  
Half-life  :  11 h  
Dose   :  2.5 to 10 mg daily  
Mechanism of action :  Felodipine inhibits the influx of extra cellular calcium 
across the myocardial and vascular smooth muscle 
cell membranes blocking the calcium channels. The 
decrease in intracellular calcium inhibits the 
contractile processes of the myocardial  smooth  
muscle  cells,  causing  dilation  of  the  coronary  and  
systemic arteries, increased oxygen delivery to the 
myocardial tissue, decreased total peripheral 
resistance, decreased systemic blood pressure, and 
decreased after load.  
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Polymer profile  
Polyethylene glycol (PEG 4000)36-38: PEG 4000 is a high molecular weight polymer  
of  ethylene  oxide  and  is  a  blend  of  polymers  with  different  degrees  of  
polymerisation.  
 
 
 
 
Synonyms : Carbowax, macrogol.  
Molecular formula : HO-CH2-(CH2-O-CH2-)n - CH2-OH  
Molecular weight :  3500-4500  
Solubility:  It  is  readily  soluble  in  water,  soluble  in  methanol,  benzene,  and 
dichloromethane and insoluble in diethyl ether and hexane.  
Melting point :  53°C to 56°C  
Storage  :  It should be stored under dry conditions and in sealed 
containers  
Uses: PEG is used as an excipient in pharmaceutical products. It is used as tablet 
binder, adhesive agent, plasticizer and lubricating agent.  
Hydroxylpropyl cellulose  (HPC)39-44:  HPC is partially substituted poly  (hydroxy 
propyl) ether of cellulose. It is non-ionic water-soluble cellulose ether with a 
versatile combination of properties. It combines dual solubility in aqueous and polar 
organic solvents,  thermoplasticity  and  surface  activity.   HPC   is   used   in   
pharmaceutical formulations for various purposes. Low-viscosity grades are used as 
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tablet binders in immediate release dosage forms and medium and high viscosity 
grades are used in sustained release matrix formulations.  
 
 
 
 
 
Chemical name: Cellulose, 2 -hydroxy propyl ether  
Synonyms: Cellulose, hydroxypropyl ether, hyprolose, Klucel and Methocel.  
Molecular weight: 50000 - 1250000  
Description: It is a white to slight yellow coloured, odourless and tasteless powder.  
Solubility: Freely soluble in water below 38°C and insoluble in water above 45°C, 
soluble in dimethyl formamide, dimethyl sulfoxide, dioxane, ethanol, methanol and 
propylene glycol.  
Category: Coating agent, emulsifying agent, stabilizing agent, suspending agent, 
tablet binder, thickening agent, viscosity increasing agent.  
Applications: Extended release matrix former, tablet binder, film Coating.  
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PLAN OF WORK 
The present work was planned with the following objectives,  
 To  prepare  felodipine  solid  binary  systems  using  polyethylene  
glycol  4000  (PEG 4000) by solvent deposition and kneading method 
at different drug: carrier ratios of 1:1, 1:3 and 1:5.  
 To prepare ternary systems with the addition of different concentrations 
of HPC to felodipine-PEG 4000 binary systems to investigate the effect 
of hydrophilic polymer on the solubility and dissolution rate of the 
felodipine.  
 To study the physicochemical characteristics of prepared solid binary 
and ternary systems by drug content, FT-IR and powder XRD studies.  
 To study the in vitro drug release profiles of all solid binary and ternary 
systems of felodipine, to study the effect of the drug-carrier ratios and 
effect of the preparation methods on drug dissolution characteristics.  
 Interpretation of in vitro dissolution data by dissolution software PCP 
DissoV3 and statistical methods using Graph Pad Instat V3.  
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MATERIALS AND METHODS 
Materials  
Table 2: List of chemicals used in the study 
Chemical name Source 
Felodipine Ajantha pharmaceuticals, Mumbai 
Methanol SD Fine chemicals,  Mumbai 
Ethanol SD Fine chemicals,  Mumbai 
PEG 4000 SD Fine chemicals,  Mumbai 
HPC SD Fine chemicals,  Mumbai 
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Methodology 
Development of UV spectroscopic method  
 To prevent the photodegradation of felodipine, all the experimental work 
was carried out under light protected conditions.  
Determination of absorption maxima: Absorption maxima are the wavelength at 
which  absorption  takes  place.  For  accurate  analytical  work  it  is  important  to 
determine the absorption maxima of the substance under study. 100 mg of felodipine 
was dissolved in 100 ml of methanol. 1 ml of this solution was pipetted out in a 
series of volumetric flask and diluted serially with 0.1N HCl  (pH  1.2) to get desired 
concentration and subjected for UV scanning in the range of  200-800 nm using 
double beam UV-VIS spectrophotometer (pharmaspec1700, Shimahdzu, Japan). The 
absorption maxima for felodipine were obtained at 239 nm with a characteristic 
peak.  
Preparation of calibration curve: Using absorption maxima a standard curve was  
prepared in the concentration range of 2-10 µg/ml. For the preparation of calibration  
curve, stock solution was prepared by dissolving  100 mg of accurately weighed  
felodipine in 100 ml of methanol. Further 1 ml of this solution was pippeted into 100  
ml of volumetric flask and diluted to 100 ml with phosphate buffer of 0.1 N HCl.  
From this, 2, 4, 6, 8 and 10 ml pipetted into a series of 10 ml volumetric flask and  
volume was made up to 10 ml with 0.1N HCl to get 2, 4, 6, 8 and 10 µg/ml of  
felodipine  respectively.  The  optical  density  values  of  resulting  solutions  were  
measured at 239 nm in double beam UV-VIS spectrophotometer (pharmaspec-1700,  
Shimadzu, Japan) and statistical data is given in table 3. The concentration versus  
optical density values are plotted and shown in the figure 1.  
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Table : 3 Calibration curve data of felodipine 
Concentration (µg/ml) Absorbance* ± SD 
2 0.051 ± 0.001 
4 0.108 ± 0.002 
6 0.161 ± 0.175 
8 0.216 ± 0.0005 
10 0.269 ± 0.001 
                        *Average of three determinations  
 
 
 
 
 
 
 
 
 
Figure 1: Calibration curve of felodipine 
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Table 4: Statistical data for calibration curve 
Absorption maxima 239 nm 
Beer’s law limit 1-20 ȝ/ml 
Molar absorptivity (mol-1cm-1) 9.807 x 103 
Coefficient of correlation 0.9999 
Best- fit values 
 
Slope 0.02704 ± 0.0001547 
Y-intercept when X=0.0 -0.001048 ± 0.000937 
X-intercept when Y=0.0 0.03874 
1/slope 36.98 
95% Confidence Intervals 
 
Slope 0.02661 to 0.02747 
P value < 0.0001 
 
Preparation of solid binary and ternary systems  
 The solid binary systems of felodipine:PEG 4000 were prepared at 1:1, 1:3 
and 1:5 w/w ratios as shown in table 5.  
Physical mixtures (PMs): The physical mixtures of felodipine and PEG 4000 at 
1:1, 1:3 and 1:5 ratios (w/w) were prepared by mixing individual components that 
had previously been passed through sieve no.120.  
Kneading method (KM): The solid binary systems of felodipine with PEG 4000 
were prepared by triturating the required quantities in a glass mortar with small 
volume of solvent blend of water and ethanol. The thick slurry was kneaded for 1 h 
and then dried at  450C until dryness. The dried mass was pulverized and passed 
through sieve no.120.  
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 Similarly physical mixtures and solid ternary systems of felodipine, PEG 
4000 and HPC (table  6) were prepared by adding different concentrations of PC 
(5%, 10% and 15% w/w of the solid binary system) to felodipine-PEG 4000 systems 
(1:3 ratio).  
Solvent deposition method (SD): The aqueous solution of PEG 4000 was dispersed 
into a solution of felodipine dissolved in methanol. The resulting mixture was stirred 
for 1 h and evaporated until dry. The dried mass was pulverized and passed through 
sieve no.120. 
Table 5: Formulae of felodipine solid binary system with PEG 4000 
Sl. 
No 
Batches 
Drug:carrier 
ratio (w/w) 
Method 
1 Felodipine:PEG4000 1:1 PM 
2 Felodipine:PEG4000 1:1 KM 
3 Felodipine:PEG4000 1:1 SD 
4 Felodipine:PEG4000 1:3 PM 
5 Felodipine:PEG4000 1:3 KM 
6 Felodipine:PEG4000 1:5 SD 
7 Felodipine:PEG4000 1:3 PM 
8 Felodipine:PEG4000 1:5 KM 
9 Felodipine:PEG4000 1:5 SD 
 
Table 6: Formulae of felodipine solid ternary system 
Sl. 
No 
Felodipine : PEG 4000 
ratio (w/w) 
% of HPC  Method 
1 1:3 5% PM 
2 1:3 5% KM 
3 1:3 10% PM 
4 1:3 10% KM 
5 1:3 15% PM 
6 1:3 15% KM 
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Characterization of solid binary and ternary systems  
Drug content uniformity: In each case PMs and solid binary/ternary systems, 
sample equivalent to 10 mg of felodipine was accurately weighed and transferred to 
100 ml volumetric flask and extracted in methanol. The volume was made up to 100 
ml with 0.1N HCl. From this 1 ml is subsequently diluted to 10 ml with 0.1N HCl 
and assayed for  felodipine  content  by  measuring  at 239  nm using  0.1N  HCl  as  
blank.  The felodipine content was calculated from the calibration curve. The 
experiments were conducted in triplicate.  
Solubility studies: The solubility measurements of felodipine were carried out by 
adding excess amount of drug (50 mg) to 20 ml of PEG 4000 prepared in 0.1N HCl 
(pH1.2) in a series of stoppered conical flasks. Then the suspensions were agitated at 
37°C ± 1°C until equilibrium was achieved. Then 2 ml aliquots were filtered, diluted 
suitably and assayed spectrophotometrically at 239 nm for felodipine content. The 
experiments were conducted in triplicate. The blanks were performed in the same 
concentrations of PEG 4000 in 0.1N HCl in order to cancel any absorbances that 
may be exhibited by the PEG 4000 molecules.  
Fourier Transform Infrared Spectrometry (FT-IR): Infrared spectra were 
obtained  using   a   Perkin   Elmer  1600   FT-IR   spectrophotometer   (USA).   The   
spectra  were recorded for felodipine, PEG 4000 and HPC, physical mixtures and all 
solid binary and ternary system. The samples were prepared by the potassium 
bromide  (KBr)  disc  method.  The  KBr  discs  were  prepared  by  compressing  the  
powder and scanning range was kept from 4000 to 450 cmí1.  
Powder X-ray diffractometry (PXRD): The powder XRD patterns of felodipine,  
PEG  4000, HPC, physical mixtures and all solid binary and ternary system were 
recorded by using Philips X-ray powder diffractometer (model PW 1710) employing 
Cu-KĮ-radiation. The diffractometer were run at 2.40/min interms of 2ș angle.  
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In vitro dissolution studies: The in vitro dissolution studies were performed for  
felodipine alone, PMs and all solid binary and ternary system using the dissolution  
rate test apparatus USPXXIV Type II by the powder dispersed amount method  
(powder samples were spread over the dissolution medium).   Felodipine 10 mg or  
physical mixture or solid binary and ternary system equivalent to 10 mg of 
felodipine was used in each test. The dissolution studies were carried out using 900 
ml of 0.1N HCl (pH 1.2), maintained at 37 ± 0.5°C with paddle rotation maintained 
at 50 rpm. The release of felodipine was measured by withdrawing 5 ml aliquot at 
regular time intervals, filtered, suitably diluted and assayed spectrophotometrically 
at  239 nm. Fresh medium was added to maintain a constant volume after each 
sampling. All dissolution experiments were conducted in triplicate. Dissolution 
results of pure drug, PMs  and  solid  binary  and  ternary  systems  were  computed  
by  using  dissolution software PCP DISSO V3.  
Statistical analysis: Statistical analysis was performed to assess the dissolution of 
felodipine from PMs, SDs and solid binary systems using Graph Pad Instat V3. The 
percent dissolution efficiency (DE) values obtained from dissolution studies of solid 
binary and ternary systems were compared with one-way ANOVA at 95% 
confidence interval using Dunnett multiple comparision test. A significance level of 
P < 0.05 was used to denote statistically significance in all cases.  
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4. RESULTS 
Table 7: Solubility studies of felodipine in different concentration of PEG 4000 
Concentration 
of PEG 4000 (% w/w) 
Concentration  of 
felodipine (µg/ ml)± SD 
2 0.09 x 103 ± 0.43 
4 0.15  x 103 ± 0.33 
6 0.23  x 103 ± 0.26 
8 0.32  x 103 ± 0.72 
10 0.40  x 103 ± 0.18 
 
 
 
 
 
 
 
 
 
Figure 2:  Solubility profile of pure felodipine in different concentration of  
PEG 4000  
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Table 8: Percentage drug content in felodipine:PEG 4000 PMs and solid  
binary systems 
Method 
Drug : carrier 
ratio (w/w) 
% Drug content + SD % Yield 
PM 1:1 96.59 ± 0.14 99.56 
PM 1:3 98.36 ± 0.22 96.25 
PM 1:5 97.74 ± 0.15 98.00 
KM 1:1 93.23 ± 0.19 97.42 
KM 1:3 95.03 ± 0.13 96.01 
KM 1:5 96.54 ± 0.36 95.87 
SD 1:1 97.18 ± 0.24 96.89 
SD 1:3 96.95 ± 0.30 96.28 
SD 1:5 97.21 ± 0.22 95.77 
 
Table 9:  Percentage drug content in felodipine:PEG 4000:HPC PMs and solid 
ternary systems 
Felodipine : PEG 
4000 ratio (w/w) 
% of HPC Method 
% Drug content 
+ SD 
% Yield 
1:3 5% PM 98.72 ± 0.13 97.48 
1:3 5% KM 97.51 ± 0.15 96.76 
1:3 10% PM 97.99 ± 0.21 97.25 
1: 3 10% KM 96.84 ± 0.12 95.99 
1:3 15% PM 98.02 ± 0.23 98.12 
1:3 15% KM 97.98 ± 0.26 96.68 
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Figure 3: FT-IR spectra of felodipine, PEG 4000 and HPC 
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Figure 4: Comparative FT-IR spectra of felodipine, PEG 4000, felodipine:PEG 
4000  PMs and solid binary system at 1:1 ratio  
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Figure 5: Comparative FT-IR spectra of felodipine, PEG 4000, felodipine:PEG 
4000 PMs and solid binary system at 1:3 ratio  
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Figure 6:  Comparative FT-IR spectra of felodipine, PEG 4000, felodipine:PEG 
4000 PMs and solid binary system at 1:5 ratio  
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Figure 7: Comparative FT-IR spectra of felodipine, PEG 4000, HPC,  felodipine: 
PEG 4000:HPC (5%) PMs and solid ternary systems  
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Figure 8: Comparative FT-IR spectra of felodipine, PEG 4000, HPC,  
felodipine: PEG 4000:HPC (10%) PMs and solid ternary systems  
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Figure 9: Comparative FT-IR spectra of felodipine, PEG 4000, HPC, 
felodipine: PEG 4000:HPC (15%) PMs and solid ternary systems  
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Table 10: Characteristic FT-IR peaks of felodipine in PMs and solid binary 
systems  of felodipine with PEG 4000  
Batches 
Characteristic peaks (cm-1 of Felodipine 
N-H Stretching C=O Stretching 
Felodipine 3368.47 1694.41 
PM 1:1 3368.68 1694.39 
KM 1:1 3322.49 1696.63 
SD 1:1 3321.79 1696.33 
PM 1:3 3368.88 1694.29 
KM 1:3 3322.77 1697.08 
SD 1:3 3323.56 1697.02 
PM 1:5 3368.58 1694.29 
KM 1:5 3325.30 1696.93 
SD 1:5 3324.37 1697.54 
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Figure 10: XRD spectra of felodipine, PEG 4000 and HPC 
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Figure 11:  Comparative XRD spectra of felodipine, PEG 4000, felodipine:PEG 4000 
PMs and solid binary system   at 1:1 ratio   
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Table 11:  XRD values of felodipine, PEG 4000 and felodipine:PEG 4000 PMs at 
1:1 ratio 
Felodipine PEG 4000 
Felodipine :PEG 4000 
1:1 (PM) 
d(A) 0ș I/I0 d(A) 0ș I/I0 d(A) 0ș I/I0 
8.32 15.8 24 5.92 22.28 11 8.36 15.72 30 
6.58 20.02 2 4.66 28.41 222 8.23 15.98 17 
5.27 25.08 13 4.04 32.88 28 7.85 16.76 8 
5.19 25.45 28 3.87 34.33 231 7.2 18.28 3 
4.22 31.44 6 3.84 34.6 279 5.3 24.9 21 
3.99 33.29 8 3.79 35.11 234 5.21 25.37 24 
3.79 35.11 42 3.41 39.23 42 4.53 29.22 14 
3.56 37.46 22 3.33 40.21 44 4.23 31.38 32 
3.44 38.78 18 3.21 41.79 14 3.97 33.46 14 
3.33 40.2 38 2.91 46.3 5 3.74 35.62 104 
3.18 42.06 12 2.74 49.23 10 3.55 37.56 27 
3 44.81 15 2.62 51.68 3 3.44 38.78 28 
2.93 45.93 12 2.55 53.35 18 3.33 40.18 42 
2.85 47.36 13 2.47 55 27 2.98 45.1 18 
2.77 48.81 7 2.27 60.37 24 2.92 46.04 11 
2.7 50.15 11 2.1 65.92 9 2.84 47.47 15 
2.46 55.32 10 2.01 69.28 9 2.76 48.97 18 
2.41 56.65 6 1.97 75.48 13 2.7 50.07 14 
2.25 60.99 10 2.62 51.74 7 
2.07 66.79 5 2.52 53.86 5 
2.03 68.56 5 2.45 55.48 9 
1.89 74.17 10 2.4 56.88 8 
1.81 78.27 7 2.25 60.92 19 
2.02 68.85 7 
1.89 74.18 10 
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Table 12: XRD values of felodipine, PEG 4000 and felodipine:PEG 4000 (1:1 
ratio) solid binary systems prepared by  kneading method 
Felodipine PEG 4000 Felodipine :PEG 4000 1:1 (PM) 
d(A) 0ș  I/I0 d(A) 0ș  I/I0 d(A) 0ș  I/I0 
8.32 15.8 24 5.92 22.28 11 6.94 18.98 4 
6.58 20.02 2 4.66 28.41 222 4.84 27.32 7 
5.27 25.08 13 4.04 32.88 28 4.57 28.97 23 
5.19 25.45 28 3.87 34.33 231 4.26 31.14 9 
4.22 31.44 6 3.84 34.6 279 4.02 33.09 10 
3.99 33.29 8 3.79 35.11 234 3.78 35.21 62 
3.79 35.11 42 3.41 39.23 42 3.48 38.3 6 
3.56 37.46 22 3.33 40.21 44 3.33 40.11 8 
3.44 38.78 18 3.21 41.79 14 2.89 46.55 7 
3.33 40.2 38 2.91 46.3 5 2.24 61.36 7 
3.18 42.06 12 2.74 49.23 10 2.09 66.31 4 
3 44.81 15 2.62 51.68 3 2.07 66.96 12 
2.93 45.93 12 2.55 53.35 18 
   
2.85 47.36 13 2.47 55 27 
   
2.77 48.81 7 2.27 60.37 24 
   
2.7 50.15 11 2.1 65.92 9 
   
2.46 55.32 10 2.01 69.28 9 
2.41 56.65 6 1.97 75.48 13 
   
2.25 60.99 10 
   
2.07 66.79 5 
   
2.03 68.56 5 
   
1.89 74.17 10 
   
1.81 78.27 7 
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Table 13:  XRD values of felodipine, PEG 4000 and felodipine:PEG 4000 (1:1 
ratio) solid binary system prepared by solvent deposition method 
 
Felodipine PEG 4000 Felodipine :PEG 4000 1:1 (PM) 
d(A) 0ș I/I0 d(A) 0ș I/I0 d(A) 0ș I/I0 
8.32 15.8 24 5.92 22.28 11 9.24 14.22 7 
6.58 20.02 2 4.66 28.41 222 8.51 15.46 4 
5.27 25.08 13 4.04 32.88 28 4.89 27.05 10 
5.197 25.45 28 3.87 34.33 231 4.6 28.8 71 
4.224 31.44 6 3.84 34.6 279 4.03 32.99 15 
3.996 33.29 8 3.79 35.11 234 3.78 35.2 132 
3.79 35.11 42 3.41 39.23 42 3.6 37 8 
3.56 37.46 22 3.33 40.21 44 3.39 39.42 17 
3.44 38.78 18 3.21 41.79 14 3.26 41.04 10 
3.33 40.2 38 2.91 46.3 5 2.7 50.06 7 
3.18 42.06 12 2.74 49.23 10 2.47 55.19 10 
3 44.81 15 2.62 51.68 3 2.26 60.84 14 
2.93 45.93 12 2.55 53.35 18 1.85 76.06 6 
2.85 47.36 13 2.47 55 27 
   2.77 48.81 7 2.27 60.37 24 
   2.7 50.15 11 2.1 65.92 9 
   2.46 55.32 10 2.01 69.28 9 
   2.41 56.65 6 1.97 75.48 13 
   2.25 60.99 10 
      2.07 66.79 5 
      2.03 68.56 5 
      1.89 74.17 10 
      1.81 78.27 7 
        
Results 
43 
Department of Pharmaceutics, AVPC 
Table 14:  XRD values for felodipine, PEG 4000 and felodipine:PEG 4000 PMs 
at 1: 3 ratio 
Felodipine PEG  4000 
Felodipine:PEG 4000 
1:3(PM) 
d(A) 0ș c d(A) 0ș I/I0 d(A) 0ș I/I0 
8.32 15.80 24 5.92 22.28 11 8.54 15.40 10 
6.58 20.02 2 4.66 28.41 222 5.88 22.43 7 
5.27 25.08  13 4.04 32.88 28 24.75 12 
5.19 25.45 28 3.87 34.33 231 4.55 29.13 61 
4.22 31.44 6 3.84 34.60 279 4.28 31.02 5 
3.99 33.29 8 3.79 35.11 234 3.83 34.70 98 
3.79 35.11 42 33.41 39.23 42 3.74 35.60 112 
3.56 37.46 22 3.33 40.21 44 3.59 37.14 7 
3.44 38.78 18 3.21 41.79 14 3.47 38.47 4 
3.33 40.20 38 2.91 46.30 5 3.35 39.85 22 
3.18 42.06 12 2.74 49.23 10 3.26 41.05 12 
3.00 44.81 15 2.62 51.68 3 2.99 44.87 10 
2.93 45.93 12 2.55 53.35 18 2.70 50.13 6 
2.85 47.36 13 2.47 55.00 27 2.47 55.03 16 
2.77 48.81 7 2.27 60.37 24 2.25 60.93 15 
2.70 50.15 11 2.10 65.92 9 2.09 66.32 6 
2.46 55.32 10 2.01 69.28 9 1.82 77.92 9 
2.41 56.65 6 1.97 75.48 13    
2.25 60.99 10       
2.07 66.79 5       
2.03 68.56 5       
1.89 74.17 10       
1.81 78.27 7       
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Table 15:  XRD values of felodipine, PEG 4000 and felodipine:PEG 4000 (1:3 
ratio) solid binary system prepared by  kneading method 
Felodipine PEG  4000 
Felodipine:PEG 4000 
1:3(PM) 
d(A) 0ș I/I0 d(A) 0ș I/I0 d(A) 0ș I/I0 
8.32 15.80 24 5.92 22.28 11 9.13 14.40 3 
6.58 20.02 2 4.66 28.41 222 8.31 15.82 3 
5.27 25.08 13 4.04 32.88 28 5.91 22.33 4 
5.19 25.45 28 3.87 34.33 231 4.53 29.22 40 
4.22 31.44 6 3.84 34.60 279 3.98 33.38 7 
3.99 33.29 8 3.79 35.11 234 3.76 35.43 121 
3.79 35.11 42 3.41 39.23 42 3.36 39.76 14 
3.56 37.46 22 3.33 40.21 44 3.26 41.01 12 
3.44 38.78 18 3.21 41.79 14 2.71 49.82 21 
3.33 40.20 38 2.91 46.30 5 2.51 54.09 7 
3.18 42.06 12 2.74 49.23 10 2.45 55.69 15 
3.00 44.81 15 2.62 51.68 3    
2.93 45.93 12 2.55 53.35 18    
2.85 47.36 13 2.47 55.00 27    
2.77 48.81 7 2.27 60.37 24    
2.70 50.15 11 2.10 65.92 9    
2.46 55.32 10 2.01 69.28 9    
2.41 56.65 6 1.97 75.48 13    
2.25 60.99 10       
2.07 66.79 5       
2.03 68.56 5       
1.89 74.17 10       
1.81 78.27 7       
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Table 16: XRD values of felodipine, PEG 4000 and felodipine:PEG 4000 (1:3 
ratio) solid binary system prepared by solvent deposition method 
Felodipine PEG  4000 
Felodipine:PEG 4000 
1:3(PM) 
d(A) 0ș I/I0 d(A) 0ș I/I0 d(A) 0ș I/I0 
8.32 15.80 24 5.92 22.28 11 9.97 13.17 3 
6.58 20.02 2 4.66 28.41 222 8.28 15.88 3 
5.27 25.08 13 4.66 28.41 28 5.96 22.14 7 
5.19 25.45 28 4.04 32.88 231 4.83 27.40 6 
4.22 31.44 6 3.84 34.60 279 4.55 29.10 22 
3.99 33.29 8 3.79 35.11 234 4.25 31.18 6 
3.79 35.11 42 3.41 39.23 42 3.98 33.43 22 
3.56 37.46 22 3.33 40.21 44 3.79 35.14 6 
3.44 38.78 18 3.21 41.79 14 3.7 34.53 12 
3.33 40.20 38 2.91 46.30 5 3.79 35.14 62 
3.18 42.06 12 2.74 49.23 10 3.7 50.17 71 
3.00 44.81 15 2.62 51.68 3 3.49 61.13 6 
2.93 45.93 12 2.55 53.35 18 2.70 50.17 4 
2.85 47.36 13 53.35 55.00 27 2.25 61.13 6 
2.77 48.81 7 55.00 60.37 24    
2.70 50.15 11 60.37 65.92 9    
2.46 55.32 10 65.92 69.28 9    
2.41 56.65 6 1.97 75.48 13    
2.25 60.99 10       
2.07 66.79 5       
2.03 68.56 5       
1.89 74.17 10       
1.81 78.27 7       
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Figure13:  Comparative XRD spectra of felodipine, PEG 4000, felodipine:PEG 4000 PMs 
and solid binary system at 1:5 ratio  
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Table 17:  XRD values for felodipine, PEG 4000 and felodipine:PEG 4000 
PMs at 1: 5 ratio 
Felodipine PEG  4000 
Felodipine:PEG 4000 
1:3(PM) 
d(A) 0ș I/I0 d(A) 0ș I/I0 d(A) 0ș I/I0 
8.32 15.80 24 5.92 22.28 11 9.90 13.27 2 
6.58 20.02 2 4.66 28.41 222 8.65 15.20 45 
5.27 25.08 13 4.04 32.88 28 8.12 16.19 16 
5.19 25.45 28 3.87 34.33 231 6.72 19.61 8 
4.22 31.44 6 3.84 35.11 279 6.08 22.53 38 
3.99 33.29 22 3.79 35.11 234 5.86 24.30 38 
3.79 35.11 42 3.41 39.23 234 5.43 24.72 46 
3.56 37.46 22 3.33 40.21 42 5.34 26.37 5 
3.44 38.78 18 3.21 41.79 44 5.01 28.59 59 
3.33 40.20 38 2.91 46.30 14 4.63 30.72 26 
3.18 42.06 12 2.74 49.23 5 4.32 32.96 22 
3.00 44.81 15 2.62 51.68 10 4.03 34.80 159 
2.93 45.81 12 2.55 55.35 3 3.82 36.81 41 
2.85 47.36 13 2.47 55.00 18 3.62 38.12 34 
2.77 48.81 7 2.27 60.37 27 3.50 39.85 46 
2.70 50.15 11 2.10 65.92 24 3.35 34.64 38 
2.46 55.32 10 2.01 69.28 9 3.02 38.95 24 
2.41 56.65 6 1.97 75.48 9 3.04 44.55 14 
2.25 60.99 10   13 2.95 45.60 19 
2.07 66.79 5    2.88 46.81 11 
1.89 74.17 10    2.78 48.46 14 
1.81 78.27 7    2.73 49.54 17 
      2.58 52.62 11 
      2.49 54.70 19 
      2.43 56.21 4 
      2.27 60.44 27 
      2.10 66.06 6 
      1.91 73.66 6 
      1.82 78.10 7 
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Table 18:  XRD values of felodipine, PEG 4000 and felodipine:PEG 4000 (1:5)  
solid binary system prepared by  kneading method 
Felodipine PEG  4000 
Felodipine:PEG 4000 
1:3(PM) 
d(A) 0ș I/I0 d(A) 0ș I/I0 d(A) 0ș I/I0 
8.32 15.80 24 5.92 22.28 11 8.45 15.56 7 
6.58 20.02 2 4.66 28.41 222 6.01 21.95 6 
5.27 25.08 13 4.04 32.88 28 5.33 24.76 10 
5.19 25.45 28 3.87 34.33 231 4.58 28.93 69 
4.22 31.44 6 3.84 34.60 279 4.28 31.00 18 
3.99 33.29 8 3.79 35.11 234 3.78 35.25 139 
3.79 35.11 42 3.41 39.23 42 3.61 36.96 7 
3.56 37.46 22 3.33 40.21 44 3.34 39.95 21 
3.44 38.78 18 3.21 41.79 14 2.46 55.30 6 
3.33 40.20 38 2.91 46.30 5 2.26 60.83 15 
3.18 42.06 12 2.74 49.23 10 2.09 66.39 5 
3.00 44.81 15 2.62 51.68 3    
2.93 45.93 12 2.55 53.35 18    
2.85 47.36 13 2.47 55.00 27    
2.77 48.81 7 2.27 60.37 24    
2.70 50.15 11 2.10 65.92 9    
2.46 55.32 10 2.01 69.28 9    
2.41 56.65 6 1.97 75.48 13    
2.25 60.99 10       
2.07 66.79 5       
2.03 68.56 5       
1.89 74.17 10       
1.81 78.27 7       
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Table 19:  XRD values of felodipine, PEG 4000 and felodipine:PEG 4000 (1:5) 
solid binary system prepared by solvent deposition method 
Felodipine PEG  4000 
Felodipine:PEG 4000 
1:3(PM) 
d(A) 0ș I/I0 d(A) 0ș I/I0 d(A) 0ș I/I0 
8.32 15.80 24 5.92 22.28 11 9.41 13.96 9 
6.58 20.02 2 4.66 28.41 222 6.09 21.94 8 
5.27 25.08 13 4.04 32.88 28 4.88 27.11 4 
5.19 25.45 28 3.87 34.33 231 4.63 28.59 64 
4.22 31.44 6 3.84 34.60 279 4.03 32.99 16 
3.99 33.29 8 3.79 35.11 234 3.80 34.99 164 
3.79 35.11 42 3.41 39.23 42 3.53 37.84 10 
3.56 37.46 22 3.33 40.21 44 3.40 39.30 26 
3.44 38.78 18 3.21 41.79 14 3.29 40.69 21 
3.33 40.20 38 2.91 46.30 5 3.20 41.90 8 
3.18 42.06 12 2.74 49.23 10 3.00 44.78 6 
3.00 44.81 15 2.62 51.68 3 2.71 49.79 5 
2.93 45.93 12 2.55 53.35 18 2.54 53.52 10 
2.85 47.36 13 2.47 55.00 27 2.47 55.10 22 
2.77 48.81 7 2.27 60.37 24 2.26 60.58 17 
2.70 50.15 11 2.10 65.92 9 2.15 64.12 3 
2.46 55.32 10 2.01 69.28 9 1.86 75.82 8 
2.41 56.65 6 1.97 75.48 13    
2.25 60.99 10       
2.07 66.79 5       
2.03 68.56 5       
1.89 74.17 10       
1.81 78.27 7       
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Figure 14: Comparative XRD spectra of felodipine, PEG 4000, HPC and  
felodipine:PEG 4000:HPC (5%) PMs and solid ternary systems  
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Table  20:  XRD values for felodipine, PEG  4000 and felodipine:PEG  
4000:HPC (5%) PMs at 1:3 ratio  
 
Felodipine PEG  4000 
Felodipine:PEG 4000 
1:3(PM) 
d(A) 0ș I/I0 d(A) 0ș I/I0 d(A) 0ș I/I0 
8.32 15.80 24 5.92 22.28 11 8.37 15.70 48 
6.58 20.02 2 4.66 28.41 222 7.88 16.70 15 
5.27 25.08 13 4.04 32.88 2 5.77 22.87 12 
5.19 25.45 28 3.87 34.33 231 5.35 24.71 35 
4.22 31.44 6 3.84 35.11 279 5.24 25.20 20 
3.99 33.29 22 3.79 35.11 234 4.56 29.04 149 
3.79 35.11 42 3.41 39.23 234 4.26 31.13 36 
3.56 37.46 22 3.33 40.21 42 3.99 33.43 36 
3.44 38.78 18 3.21 41.79 44 3.82 34.87 110 
3.33 40.20 38 2.91 46.30 14 3.77 35.30 202 
3.18 42.06 12 2.74 49.23 5 3.72 35.78 108 
3.00 44.81 15 2.62 51.68 10 3.57 37.31 30 
2.93 45.81 12 2.55 55.35 3 3.46 38.60 55 
2.85 47.36 13 2.47 55.00 18 3.32 40.26 49 
2.77 48.81 7 2.27 60.37 27 3.16 42.38 12 
2.70 50.15 11 2.10 65.92 24 2.99 44.87 15 
2.46 55.32 10 2.01 69.28 9 2.92 46.09 23 
2.41 56.65 6 1.97 75.48 9 2.77 48.82 17 
2.25 60.99 10   13 2.71 49.94 15 
2.07 66.79 5    2.64 51.32 4 
1.89 74.17 10    2.46 55.40 12 
1.81 78.27 7    2.41 56.65 8 
      2.26 60.76 20 
*HPC is amorphous in nature  
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Table 21:  XRD values for felodipine, PEG 4000 and felodipine:PEG 
4000:HPC (5%) solid ternary systems at 1:3 ratio  
Felodipine PEG  4000 
Felodipine:PEG 4000 
1:3(PM) 
d(A) 0ș I/I0 d(A) 0ș I/I0 d(A) 0ș I/I0 
8.32 15.80 24 5.92 22.28 11 8.37 15.71 13 
6.58 20.02 2 4.66 28.41 222 5.34 24.73 8 
5.27 25.08 13 4.66 28.41 28 4.55 29.09 64 
5.19 25.45 28 4.04 32.88 231 4.25 31.20 13 
4.22 31.44 6 3.84 34.60 279 3.98 33.43 18 
3.99 33.29 8 3.79 35.11 234 3.76 35.45 137 
3.79 35.11 42 3.41 39.23 42 3.59 37.17 16 
3.56 37.46 22 3.33 40.21 44 3.47 38.44 14 
3.44 38.78 18 3.21 41.79 14 3.30 40.48 40 
3.33 40.20 38 2.91 46.30 5 3.17 42.34 9 
3.18 42.06 12 2.74 49.23 10 2.71 49.87 10 
3.00 44.81 15 2.62 51.68 3 2.46 55.29 13 
2.93 45.93 12 2.55 53.35 18 2.25 61.00 15 
2.85 47.36 13 53.35 55.00 27    
2.77 48.81 7 55.00 60.37 24    
2.70 50.15 11 60.37 65.92 9    
2.46 55.32 10 65.92 69.28 9    
2.41 56.65 6 1.97 75.48 13    
2.25 60.99 10       
2.07 66.79 5       
2.03 68.56 5       
1.89 74.17 10       
1.81 78.27 7       
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Figure 15:  Comparative XRD spectra of felodipine, PEG 4000, HPC and 
felodipine:PEG 4000:HPC (10%) PMs and solid ternary systems  
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Table  22: XRD values for felodipine, PEG  4000 and felodipine: PEG  
4000:HPC (10%) PMs at 1:3 ratio  
Felodipine PEG  4000 
Felodipine:PEG 4000 
1:3(PM) 
d(A) 0ș I/I0 d(A) 0ș I/I0 d(A) 0ș I/I0 
8.32 15.80 24 5.92 22.28 11 8.48 15.50 45 
6.58 20.02 2 4.66 28.41 222 8.01 16.43 8 
5.27 25.08 13 4.66 28.41 28 7.27 18.11 6 
5.19 25.45 28 4.04 32.88 231 6.70 19.67 5 
4.22 31.44 6 3.84 34.60 279 6.06 21.75 12 
3.99 33.29 8 3.79 35.11 234 5.84 22.59 10 
3.79 35.11 42 3.41 39.23 42 5.40 24.47 24 
3.56 37.46 22 3.33 40.21 44 5.29 24.98 22 
3.44 38.78 18 3.21 41.79 14 4.61 28.75 172 
3.33 40.20 38 2.91 46.30 5 4.29 30.93 20 
3.18 42.06 12 2.74 49.23 10 4.01 33.13 23 
3.00 44.81 15 2.62 51.68 3 3.84 34.63 110 
2.93 45.93 12 2.55 53.35 18 3.80 35.06 222 
2.85 47.36 13 53.35 55.00 27 3.75 35.55 117 
2.77 48.81 7 55.00 60.37 24 3.61 36.94 35 
2.70 50.15 11 60.37 65.92 9 3.49 38.27 29 
2.46 55.32 10 65.92 69.28 9 3.34 40.05 41 
2.41 56.65 6 1.97 75.48 13 3.29 40.61 26 
2.25 60.99 10    3.18 42.08 10 
2.07 66.79 5    3.01 44.65 12 
2.03 68.56 5    2.94 45.79 12 
1.89 74.17 10    2.88 46.81 9 
1.81 78.27 7    2.78 48.59 13 
      2.72 49.68 18 
      2.47 55.14 13 
      2.26 60.83 15 
      2.09 66.33 7 
*HPC is amorphous in nature  
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Table 23:  XRD values for felodipine, PEG 4000 and felodipine:PEG 4000:HPC 
(10%) solid ternary system at 1:3 ratio  
 
Felodipine PEG  4000 
Felodipine:PEG 4000 
1:3(PM) 
d(A) 0ș I/I0 d(A) 0ș I/I0 d(A) 0ș I/I0 
8.32 15.80 24 5.92 22.28 11 8.43 15.60 10 
6.58 20.02 2 4.66 28.41 222 5.92 22.27 7 
5.27 25.08 13 4.04 32.88 28 5.28 25.00 9 
5.19 25.45 28 3.87 34.33 231 4.59 28.85 44 
4.22 31.44 6 3.84 34.60 279 4.28 31.01 10 
3.99 33.29 8 3.79 35.11 234 3.76 35.36 112 
3.79 35.11 42 3.41 39.23 42 3.58 37.21 7 
3.56 37.46 22 3.33 40.21 44 3.47 38.47 6 
3.44 38.78 18 3.21 41.79 14 3.32 40.22 23 
3.33 40.20 38 2.91 46.30 5 2.47 55.18 10 
3.18 42.06 12 2.74 49.23 10 2.26 60.86 13 
3.00 44.81 15 2.62 51.68 3 2.09 66.35 7 
2.93 45.93 12 2.55 53.35 18    
2.85 47.36 13 2.47 55.00 27    
2.77 48.81 7 2.27 60.37 24    
2.70 50.15 11 2.10 65.92 9    
2.46 55.32 10 2.01 69.28 9    
2.41 56.65 6 1.97 75.48 13    
2.25 60.99 10       
2.07 66.79 5       
2.03 68.56 5       
1.89 74.17 10       
1.81 78.27 7       
*HPC is amorphous in nature  
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Figure 16: Comparative XRD spectra of felodipine, PEG 4000, HPC and 
felodipine:PEG 4000:HPC (15%) PMs and solid ternary systems  
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Table 24:  XRD values for felodipine, PEG 4000 and felodipine:PEG 
4000:HPC (15%) PMs at 1:3 ratio  
Felodipine PEG  4000 
Felodipine:PEG 4000 
1:3(PM) 
d(A) 0ș I/I0 d(A) 0ș I/I0 d(A) 0ș I/I0 
8.32 15.80 24 5.92 22.28 11 8.44 15.59 71 
6.58 20.02 2 4.66 28.41 222 5.89 22.38 5 
5.27 25.08 13 4.66 28.41 28 5.35 24.69 13 
5.19 25.45 28 4.04 32.88 231 4.69 28.23 7 
4.22 31.44 6 3.84 34.60 279 4.56 31.12 19 
3.99 33.29 8 3.79 35.11 234 4.26 33.39 23 
3.79 35.11 42 3.41 39.23 42 3.82 34.81 86 
3.56 37.46 22 3.33 40.21 44 3.78 35.24 172 
3.44 38.78 18 3.21 41.79 14 3.72 34.77 81 
3.33 40.20 38 2.91 46.30 5 3.58 37.20 18 
3.18 42.06 12 2.74 49.23 10 3.47 38.48 18 
3.00 44.81 15 2.62 51.68 3 3.36 39.72 34 
2.93 45.93 12 2.55 53.35 18 3.33 40.17 44 
2.85 47.36 13 53.35 55.00 27 3.00 44.82 9 
2.77 48.81 7 55.00 60.37 24 2.93 45.93 9 
2.70 50.15 11 60.37 65.92 9 2.70 50.00 10 
2.46 55.32 10 65.92 69.28 9 2.60 54.82 14 
2.41 56.65 6 1.97 75.48 13 2.47 55.08 18 
2.25 60.99 10    2.26 60.80 23 
2.07 66.79 5       
2.03 68.56 5       
1.89 74.17 10       
1.81 78.27 7       
*HPC is amorphous in nature  
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Table 25:  XRD values for felodipine, PEG 4000 and felodipine:PEG 4000:HPC 
(15%) solid ternary system at 1:3 ratio  
Felodipine PEG  4000 
Felodipine:PEG 4000 
1:3(PM) 
d(A) 0ș I/I0 d(A) 0ș I/I0 d(A) 0ș I/I0 
8.32 15.80 24 5.92 22.28 11 9.28 14.16 4 
6.58 20.02 2 4.66 28.41 222 5.97 22.07 6 
5.27 25.08 13 4.04 32.88 28 5.33 24.79 4 
5.19 25.45 28 3.87 34.33 231 4.59 28.87 34 
4.22 31.44 6 3.84 34.60 279 3.80 35.00 71 
3.99 33.29 8 3.79 35.11 234 2.47 55.17 9 
3.79 35.11 42 3.41 39.23 42 2.11 65.53 8 
3.56 37.46 22 3.33 40.21 44    
3.44 38.78 18 3.21 41.79 14    
3.33 40.20 38 2.91 46.30 5    
3.18 42.06 12 2.74 49.23 10    
3.00 44.81 15 2.62 51.68 3    
2.93 45.93 12 2.55 53.35 18    
2.85 47.36 13 2.47 55.00 27    
2.77 48.81 7 2.27 60.37 24    
2.70 50.15 11 2.10 65.92 9    
2.46 55.32 10 2.01 69.28 9    
2.41 56.65 6 1.97 75.48 13    
2.25 60.99 10       
2.07 66.79 5       
2.03 68.56 5       
1.89 74.17 10       
1.81 78.27 7       
*HPC is amorphous in nature  
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Table 26: In vitro dissolution data of solid binary system of felodipine with 
PEG 4000 at 1:1 ratio  
Time 
(min) 
Cumulative percent of drug relased (+ SD,n=3) 
Felodipine PM SD KM 
10 3.52 ± 0.01 6.83 ± 0.21 13.45 ± 0.19 13.58 ± 0.33 
20 6.79 ± 0.03 10.08 ± 0.17 16.66 ± 0.22 23.24 ± 0.45 
30 10.03 ± 0.02 13.30 ± 0.18 19.84 ± 0.21 29.66 ± 0.32 
45 13.27 ± 0.06 16.48 ± 0.27 36.00 ± 0.28 42.51± 0.48 
60 16.38 ± 0.01 22.85 ± 0.26 48.73 ± 0.30 51.97 ± 0.27 
90 25.94 ± 0.01 32.37 ± 0.23 58.11± 0.27 64.54 ± 0.54 
120 32.19 ± 0.02 41.76 ± 0.25 70.57 ± 0.26 73.76 ± 0.65 
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Figure 17:  Dissolution profile of felodipine in 0.1N HCl  (a) without model 
fitting (b) with model fitting  
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     (a)       (b) 
Figure 18:  Dissolution profile of felodipine:PEG 4000 PMs at 1:1 ratio (a) 
 without model fitting (b) with model fitting 
 
 
 
 
 
 
 
 (a)         (b)  
Figure 19:  Dissolution profile of felodipine:PEG 4000 solid binary system 
(SD)  at  1:1  ratio  (a)  without  model  fitting  (b)  with  model  fitting  
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  (a)         (b)  
Figure 20: Dissolution profile of felodipine:PEG 4000 solid binary system 
(KM) at 1:1 ratio (a) without model fitting   (b) with model fitting  
Table 27:  In vitro dissolution data of solid binary system of felodipine with 
PEG  4000 at 1:3 ratio  
Time 
(min) 
Cumulative percent of drug relased (+ SD,n=3) 
Felodipine PM SD KM 
10 3.52 ± 0.01 6.83 ± 0.23 13.45± 0.17 14.54 ± 0.32 
20 6.79 ± 0.03 10.08 ± 0.17 26.54 ± 0.24 28.21 ± 0.43 
30 10.03 ± 0.02 15.30 ± 0.18 32.93 ± 0.21 36.20 ± 0.30 
45 13.22 ± 0.06 22.98 ± 0.27 45.76 ± 0.26 49.01 ± 0.47 
60 16.38 ± 0.01 26.09 ± 0.24 55.20 ± 0.30 61.68 ± 0.24 
90 25.94 ± 0.01 35.59 ± 0.14 64.54 ± 0.26 67.76 ± 0.56 
120 32.19 ± 0.02 44.98 ± 0.25 76.96 ± 0.24 80.16 ± 0.62 
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 (a)        (b)  
Figure 21:  Dissolution profiles of felodipine:PEG 4000 PMs at 1:3 ratio (a) 
without model fitting (b) with model fitting  
 
(a)       (b) 
 
 
 
 
 
Figure 22:  Dissolution profile of felodipine:PEG 4000 solid binary system 
(SD) at 1:3 ratio (a) without model fitting (b) with model fitting  
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(a)       (b) 
Figure23:  Dissolution profile of felodipine:PEG 4000 solid binary system 
(KM) at 1:3 ratio (a) without model fitting (b) with model fitting  
Table 28:  In vitro dissolution data of solid binary system of felodipine with  
PEG 4000 at 1:5 ratio  
Time 
(min) 
Cumulative percent of drug relased (+ SD,n=3) 
Felodipine PM SD KM 
10 3.52 ± 0.01 12.12 ± 0.21 16.76 ± 0.19 18.76 ± 0.28 
20 6.79 ± 0.03 13.37 ± 0.17 26.54 ± 0.22 28.54 ± 0.24 
30 10.03 ± 0.02 16.57 ± 0.18 42.75 ± 0.21 52.75 ± 0.26 
45 13.27 ± 0.06 19.73 ± 0.27 49.08 ± 0.28 62.08 ± 0.48 
60 16.38 ± 0.01 32.56 ± 0.26 61.60 ± 0.30 71.60 ± 0.27 
90 25.94 ± 0.01 42.07 ± 0.11 77.41 ± 0.27 79.41 ± 0.52 
120 32.19 ± 0.02 48.12 ± 0.25 83.36 ± 0.26 86.36 ± 0.58 
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(a)       (b) 
Figure 24: Dissolution profile of felodipine:PEG 4000 PMs at 1:5 ratio (a) 
without model fitting (b) with model fitting 
 
(a)       (b) 
Figure 25:  Dissolution profile of felodipine : PEG 4000 solid binary system 
(SD) at 1:5 ratio (a) without model fitting (b) with model fitting  
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(a)       (b) 
Figure 26: Dissolution profile of felodipine: PEG 4000 solid binary system 
(KM) at 1:5 ratio (a) without model fitting (b) with model fitting  
 
Figure 27:  Comparative dissolution profiles of felodipine:PEG 4000 PMs 
and solid binary systems at 1:1 ratio 
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Figure 28:  Comparative dissolution profiles of felodipine:PEG 4000 PMs and 
solid binary systems at 1:3 ratio 
 
Figure 29:  Comparative dissolution profile of felodipine:PEG 4000 PMs and 
solid binary system at 1:5 ratio 
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Table 29:  Various dissolution parameters of felodipine, felodipine: PEG 
4000 PMs and solid binary systems  
Methods Drug: carrier ratio (w/w) 
DE30 
(%) 
DE60 
(%) 
DP30 
(%) 
T50 
(min) RDR30 MDT120 
Felodipine ---- 5.41 9.31 10.03 213.6 1 55.83 
PM 1:1 8.43 12.86 13.30 156 1.32 55.09 
SD 1:1 13.93 24.54 19.84 68.8 1.9 49.07 
KM 1:1 17.76 29.71 29.66 60.1 2.95 44.02 
PM 1:3 10.90 14.61 15.30 137.9 1.52 53.07 
SD 1:3 18.76 32.16 32.93 56.1 3.28 43.72 
KM 1:3 20.50 34.02 36.20 50.1 3.60 42.10 
PM 1:5 12.12 17.34 16.57 119.6 1.65 47.11 
SD 1:5 21.04 36.52 42.75 44.3 4.26 39.76 
KM 1:5 22.67 42.4 52.56 39.5 5.24 36.45 
 
 Where, DE= Dissolution efficiency after 30 and 60 min, DP= percent of 
drug dissolved after 30 min (DP), T50 = time necessary to dissolve 50% drug and 
RDR = relative dissolution rate  
Table 30:  Mathematical modeling and comparative kinetic values of 
felodipine, felodipine:PEG 4000 PMs and solid binary systems 
Methods Drug : carrier ratio (w/w) 
First order rates K1x102 
(min-1) 
Hix.Crow KHC x 102 
(mg1/3.min1) 
r K1 r KHC 
Felodipine ---- 0.9967 -0.0038 0.9927 -0.0012 
PM 1:1 0.9916 -0.0044 0.9897 -0.0014 
SD 1:1 0.9934 -0.0101 0.9904 -0.0029 
KM 1:1 0.9971 -0.0115 0.9875 -0.0032 
PM 1:3 0.9968 -0.0050 0.9945 -0.0016 
SD 1:3 0.9947 -0.124 0.9833 -0.0034 
KM 1:3 0.9911 -0.00137 0.9771 -0.0037 
PM 1:5 0.9966 -0.0058 09815 -0.0018 
SD 1:5 0.9955 -0.0157 0.9829 -0.0046 
KM 1:5 0.9822 0.0177 0.9572 -0.0041 
Where, K1 KHC, = release rate constants for First order and Hixon Crowell’s model 
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Table 31:  In vitro dissolution data of felodipine and felodipine:PEG 4000:HPC solid ternary system 
Time (min) 
Cumulative percent of drug released (+SD, n=3) 
Felodipine 
Felodipine : PEG 4000 : HPC solid ternary systems 
HPC 5% 
PM 
HPC 5% 
KM 
HPC 10% 
PM 
HPC 10% 
KM 
HPC 15% 
PM 
HPC 15% 
KM 
10 3.52 ± 0.01 6.87 ± 0.48 20.07 ± 0.58 10.14 ± 0.48 26.68 ± 0.52 13.5 ± 0.43 33.30 ± 0.46 
20 6.79 ± 0.03 10.14 ± 0.38 29.83 ± 0.57 13.37 ± 0.35 33.12 ± 0.37 15.76 ± 0.54 52.86   ± 0.70 
30 10.03 ± 0.02 16.88 ± 0.27 42.75 ± 0.70 18.88 ± 0.47 59.11 ± 0.64 19.04 ± 0.25 72.20   ± 0.41 
45 13.27 ± 0.06 22.98 ± 0.58 62.03 ± 0.34 26.24 ± 0.58 68.54 ± 0.36 26.24 ± 0.65 78.30 ± 0.53 
60 16.38 ± 0.01 29.32 ± 0.48 68.15 ± 0.26 35.79 ± 0.57 77.85 ± 0.44 35.78 ± 0.70 84.32   ± 0.62 
90 25.94 ± 0.01 45.24 ± 0.35 80.62 ± 0.64 47.24 ± 0.64 83.84 ± 0.66 51.67 ± 0.63 93.49 ± 0.42 
120 32.19 ± 0.02 51.38 ± 0.28 89.75 ± 0.27 54.57 ± 0.59 92.95 ± 0.73 57.77 ± 0.64 96.15 ± 0.34 
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(a) 
 
(b) 
Figure 30:  Dissolution profile of felodipine:PEG 4000:HPC 5% (PMs) at 1:3 
ratio a) without model fitting  b) with model fitting  
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(a) 
 
(b) 
Figure 31:  Dissolution profile of felodipine:PEG 4000:HPC 5% (KM) at 1:3 
ratio  a) without model fitting  b) with model fitting  
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(a) 
 
(b) 
Figure 32:  Dissolution profile of felodipine:PEG 4000:HPC (10%) PMs at 
1:3ratio a) without model fitting b) with model fitting  
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(a) 
 
(b) 
Figure 33:   Dissolution profile of felodipine:PEG 4000:HPC 10% (KM) at 
1:3 ratio a) without model fitting    b) with model fitting  
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(a) 
 
(b) 
Figure 34 Dissolution profile of felodipine:PEG 4000:HPC (15%) PMs at 
1:3 ratio a) without model fitting b) with model fitting 
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(a) 
 
(b) 
Figure 35:  Dissolution profile of felodipine:PEG 4000:HPC 15% (KM) at 
1:3 ratio a) without model fitting    b) with model fitting  
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Figure 36:  Comparative dissolution profiles of felodipine and PEG 4000 PMs 
and solid ternary systems at 1:3 ratio 
 
Table 32:  Various dissolution parameters of felodipine, felodipine:PEG 
4000:HPC PMs and solid ternary systems 
Methods 
Drug: 
carrier 
ratio 
(w/w) 
DE30 
(%) 
DE60 
(%) 
DP30 
(%) 
T50 
(min) RDR30 MDT120 
Felodipine ---- 5.41 9.31 10.03 213.6 1 55.83 
PM 5% 11.24 16.94 16.88 111.9 1.68 50.24 
KM 5% 24.34 41.54 42.75 36.6 4.15 38.89 
PM 10% 12.24 18.56 18.08 103.8 1.8 49.89 
KM 10% 33.11 51.22 62.83 30.06 6.21 32.32 
PM 15% 13.45 19.24 19.04 93.30 1.89 48.89 
KM 15% 41.90 60.09 72.20 23.4 7.19 25.18 
 
Where,  DE= Dissolution efficiency after 30 and 60 min, DP= percent of drug 
dissolved after 30 min (DP), T50 = time necessary to dissolve 50% drug and RDR = 
relative dissolution rate  
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Table 33: Mathematical modeling and comparative kinetic values of felodipine, 
felodipine: PEG 4000:HPC PMs and solid ternary systems 
Methods 
Drug : carrier 
ratio (w/w) 
First order rates K1x102 
(min-1) 
Hix.Crow KHC x 102 
(mg1/3.min1) 
r K1 r KHC 
 
Felodipine 
 
----- 0.9967 -0.0038 0.9927 -0.0012 
PM 5% 0.9922 -0.0062 0.9897 -0.0019 
KM 5% 0.9976 -0.0190 0.9839 -0.0048 
PM 10% 0.9952 -0.0067 0.9813 -0.0020 
KM 10% 0.9838 -0.0226 0.9438 -0.0055 
PM 15% 0.9949 -0.0075 0.9927 -0.0022 
KM 15% 0.9830 -0.0296 0.9165 -0.0066 
 
Where, K1 KHC, = release rate constants for First order and Hixon Crowell’s model  
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DISCUSSION 
 Felodipine is used as an antihypertensive and antianginal drug, belongs to  
BCS class II drug (low solubility and high permeability). It undergoes extensive first 
pass metabolism with a bioavailability of only about 15%. The major drawback in 
the therapeutic application and efficacy of felodipine as oral dosage form is its low 
aqueous solubility.  Hence this work was planned to improve dissolution 
characteristics of the model drug by increasing its release and solubility through 
solid dispersion technique.  Solid binary systems  of  felodipine  with  PEG 4000  
were prepared by kneading and solvent deposition method at different drug:carrier 
ratios. In the next phase, ternary systems were prepared by kneading method with 
the addition of different concentrations of HPC to felodipine:PEG 4000 (1:3 ratio) 
binary systems to investigate the effect of hydrophilic polymer on the solubility and 
dissolution rate of the felodipine.  
 All prepared solid binary and ternary systems were found to be fine and 
free flowing. The characterization of binary and ternary systems was performed by 
FT-IR and powder X-ray diffractometry. The in vitro dissolution results of 
felodipine, PMs, solid binary and ternary systems were computed by using 
dissolution software PCP DISSO V3.  
Solubility studies of pure felodipine in different concentration of PEG 4000  
 An effect of PEG 4000 on the solubility of felodipine was studied and the 
results are summarized in table  7  and displayed in figure   2. The solubility of 
felodipine was found to be 0.09 × 103, 0.15 × 103, 0.23 × 103, 0.32 × 103 and 0.40 × 
103 µg/ml  at  2%,  4%,  6%,  8%  and  10%  (w/v)  of  PEG  4000  concentration 
respectively. The solubility studies showed that solubility of felodipine increased 
linearly as a function of concentration of the carrier. These results are in accordance 
with the well established formation of weak water soluble complexes between water 
soluble polymeric carriers and poorly soluble drugs45.  
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Percentage drug content  
 The percentage drug content results of PMs and all binary and ternary 
systems of felodipine are shown in table  8 and in table  9 respectively. The drug 
content was found to be in the range of 93.23 to 98.36 % for binary systems and 
97.51 to 98.72 % for ternary systems. Low standard deviation (SD) values (i.e., < 1) 
indicated uniform drug distribution in all prepared batches. The overall yield of 
binary and ternary systems of felodipine was in the range of 95.87 to 99.56 % and 
95.99 to 98.12 %.  
Fourier transform-IR studies  
 To study the possible interactions between the felodipine, PEG 4000 and 
HPC in the solid state, IR spectra of binary and ternary systems were compared with 
the  drug  alone.  The  IR  spectrum  of  felodipine,  PEG  4000  and  HPC  are  shown  in  
figure 3. The IR spectrum of felodipine exhibit characteristic peaks for amide group  
(N-H streching) at 3368.47     cm-1, aromatic C-H stretching at 3072.26 cm-1 and 
1694.41 cm-1 due to C=O stretching. A very distinctive peak for PEG 4000 was a 
broad band at 3426.51 cm-1 that represents the stretching vibration for the OH 
groups. Other important vibrations detected in the spectrum of PEG 4000 were C-H 
stretching at 2286.80 cm-1 and C-O stretching at 1111.15 cm-1.  
  The comparative FT-IR spectrum of felodipine, PEG 4000, PMs and its 
solid binary systems prepared by all methods at 1:1, 1:3 and 1:5 ratios are displayed 
in figures 4, 5 and 6 respectively. The characteristics peaks of felodipine, PMs and 
solid binary systems prepared at all ratios are summarized in table 10. The  PMs  
showed almost same characteristic peaks of drug indicating no interaction. In the 
spectra of 1:1, 1:3 and 1:5 ratios prepared by kneading and solvent deposition 
method, N-H stretching of amide group of the felodipine is shifted towards lower 
wavelength table 10. Similar results were observed with solid the ternary systems. 
The intensity and shape of these bands changed dramatically in all solid binary and 
ternary systems. A decrease in the intensity of bands may also be due to the amount 
of compounds. However, little shifts in the stretching vibration due to -CH2 groups 
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of PEG 4000 appeared at wave numbers 2286.80 cm-1 suggesting the possible 
difference in the degree of interaction between drug and carriers in PMs, solid 
binary and ternary systems. Further, C=O stretching of felodipine in all solid binary 
systems slightly shifted to higher wavelength. These significant changes indicate the 
possibility  of  intermolecular   hydrogen   bonding   between   amide   group   of   the   
felodipine  and hydroxyl group of the PEG 4000. In the low frequency region (1500-
500 cm-1) of spectra of solid binary and ternary systems, the characteristic peaks of 
felodipine were almost unchanged.  This indicated that overall symmetry of the  
molecule  is  not significantly affected even though the drug molecule is hydrogen 
bonded with the carrier.  
Powder X-ray diffraction studies  
 Crystallinity has a great impact on the solubility and dissolution rate of 
poorly water soluble drugs. The powder XRD pattern of pure felodipine and PEG 
4000 and HPC are shown in figure 10. Comparative 2ș peak values of felodipine, 
PMs and solid binary systems are presented in tables  11 to  19 and their XRD 
pattern of felodipine, PMs and solid binary systems are shown in figures  11,  12 
and  13 respectively.  Many  diffraction  peaks  with  high  intensity  were  observed  
in  the diffraction pattern of felodipine due to its crystallinity. Few peaks with high 
intensity were observed in the diffraction pattern of PEG 4000. The spectrum of 
HPC was characterized by complete absence of any diffraction peaks. All principle 
peaks of felodipine were present in PMs. On the other hand, the diffraction pattern 
of all solid binary systems at 1:1, 1:3 and 1:5 ratios showed principle peaks of 
felodipine with significant decrease in the intensity of peak indicating the reduction 
in crystallinity. The intensity of felodipine at 15.80, 25.45 and 35.11(2 ) remarkably 
reduced in solid binary systems. However in the solid binary systems prepared by 
kneading method at 1:5 ratios, the crystallinity of felodipne was found to be reduced 
to a greater extent, evidenced by marked reduction in the number as well as the 
intensity of peaks.  
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 X-ray  diffractograms  of  felodipine,  PMs  and  solid  ternary  systems  of  
felodine:PEG 4000:HPC 5%, 10% and 20%   prepared by kneading method are 
shown in figures 14, 15 and 16 respectively. The XRD pattern of ternary systems 
differs significantly from that of the PMs. Also, the effect of HPC concentration on 
the drug crystallinity was evident from the XRD studies. A marked reduction in the 
number  as  well  as  the  intensity  of  peaks  was  observed  in  case  of  ternary  systems  
prepared at 15%  HPC.  The  XRD  results  of  all  solid  binary  and  ternary  ystems  
indicated significant reduction in the felodipine crystallinity.  
In vitro dissolution behaviour of solid binary and ternary systems  
 The in vitro dissolution studies of felodipine, PMs,   solid binary and 
ternary systems prepared by kneading and solvent deposition method were carried 
out in 0.1 N HCl (pH 1.2)   up to period of 120 min using USP Dissolution apparatus 
type  II.   In vitro dissolution data was evaluated on the basis of cumulative 
percentage drug release Vs time profile. The in vitro results all solid binary and 
ternary systems and their corresponding PMs were compared with the pure 
felodipine. The percentage of felodipine dissolved at 30 min (DP30) and dissolution 
efficiency 30 min (DE30)  and  at  60  min  (DE60); the characteristic time for 50% 
dissolution of felodipine (T50 min) and mean dissolution time (MDT) were 
calculated for all solid binary and ternary systems. Khan47 suggested the ‘dissolution 
efficiency’ (DE) as a suitable parameter for the in vitro dissolution data. It is defined 
as  the  area  under  the  dissolution  curve  up  to  a  certain  time  ‘t’,  expressed  as  a  
percentage of the area of the rectangle described by 100% dissolution in the same 
time.  
t
ȕȜ x dtDissolution efficiancy (DE) = x100
Ȟ md x t
ª º
« »
« »¬ ¼
³  
 The in vitro dissolution data of felodipine, PMs and solid binary systems  
studied in  0.1N HCl are presented in table  26,  27 and  28 respectively and their  
dissolution profiles (with and without model fitting) are shown in figure 17 to 26.  
The   comparative   dissolution   profiles   of   felodipine,   PMs   and   all   binary   
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systems prepared at 1:1, 1:3 and 1:5 are shown in figure 27, 28 and 29 respectively. 
Various dissolution parameters such as DE30, DE60, DP30, T50, RDR30 and MDT of 
solid binary systems are summarized in table  29.    Dissolution  profiles  were  also  
analysed according to two release models i.e., first order and Hixson-Crowell cube 
root model. The calculated release rate constants ‘K’ and `r’ values of these models 
for solid binary systems are summarized in table 30.  
 The dissolution of drug alone was incomplete even after 120 minutes. The 
in vitro dissolution studies indicated higher dissolution rate of felodipine from solid  
binary systems compared to felodipine alone and the corresponding PMs. The DE30  
and DE60 values of the solid binary systems prepared by kneading and solvent  
deposition methods were relatively high compared to the values from the PMs and  
felodipine alone. The value of T50 and MDT of all solid binary systems were lower  
than felodipine alone. Further, it was found that the drug dissolution was higher in 
1:5 (drug:carrier ratio) compared to 1:1 and 1:3 ratios. These observations indicated 
the enhanced dissolution of solid binary systems with increase in the concentration 
of PEG 4000, possibly due to drug particle size reduction as well as decrease in the  
crystallinity of drug during course of the solid dispersion preparation. The overall 
the rank order of improvement in dissolution properties of felodipine with different  
methods in all ratios was found in the following rank order,  
 KM > SD >PMs > Felodipine 
 The DE30 and DE60 values of the solid binary systems prepared by 
kneading method were higher compared to solid binary systems prepared by solvent 
deposition methods. This may be attributed to the less crystallinity of drug in solid 
binary systems prepared by kneading methods. These results are further supported 
by other parameters such as XRD and FT-IR studies.  
 In the next phase, solid ternary systems were prepared by kneading method 
using HPC in different concentrations (5%, 10% and 15% w/w of the solid binary 
system) to study the effect of hydrophilic polymer on the drug release. The in vitro 
dissolution data of felodipine, PMs and solid ternary systems are summarized in 
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table 31. Their respective dissolution profiles and comparative graphs are shown in 
figures 30 to 35 and figures 36 respectively. The slight increase noted in the 
dissolution rate in the PMs of binary and ternary systems might be due to the 
‘microenvironment effect’ in binary systems and ability of the hydrophilic polymer 
(HPC) to increase drug wettability in case of ternary systems. All ternary systems 
exhibited a significant increase in dissolution rate with respect to the PMs and the 
reference drug. It was noted  that  the  dissolution  rate  was  progressively  increased  
with  increasing concentration of HPC in the ternary systems. Ternary system with 
HPC 15% showed the most significant effect on the dissolution properties of drug. 
The increase in dissolution rate of felodipine in ternary systems with different 
concentration of HPC was found in the following order,  
 HPC 15% > HPC 10% > HPC 5% 
 In addition to the size reduction of the crystalline felodipine in binary 
systems, the faster dissolution rate of the drug exhibited in ternary systems might be 
due to excellent wettability and dispersibility of drug from a solid dispersion system 
due to the presence of higher concentration of water soluble carrier HPC. Usually in 
solid dispersions, the drug is partially dissolved in melted or dissolved polymer. 
After drying of these solid dispersions, the drug will not nucleate to form firm 
crystals resulting in formation of microcrystals. Drug microcrystals are embedded in 
the water-soluble matrix, where hydrophilic polymers present the ability of rapid 
wetting and thereby dissolution of drug47. The release pattern in felodipine, PMs and 
all solid binary and ternary systems were found to be first order (best fit model) 
compared to Hixson-Crowell’s cube root model. These results were observed based 
on the highest correlation coefficient ‘r’ values.  
 To analyse the statistical significance of difference between PMs, solid 
binary  and   ternary   systems  and   pure   drug,   one-way  ANOVA  with   Dunnett   
multiple comparison test was used. Obtained p  <  0.05 were considered to be 
statistically  significant.  Significant  differences  in  the  means  of  DE30 values of 
felodipine, PMs, solid binary and ternary systems were tested at 95% confidence. 
The DE30 values of PMs, solid binary and ternary systems were significantly higher 
(P < 0.01) compared to the DE30 values of felodipine alone.  
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SUMMARY 
 
 The present study was planned to improve solubility and dissolution rate 
of felodipine (BCS class II drug) through solid dispersion technique using water 
soluble carriers.  Solid  binary  systems  of  felodipine  with  PEG 4000  were  
prepared  by kneading and solvent deposition method at different drug:carrier ratios. 
In the next phase, ternary systems were prepared by kneading method with addition 
of  different  concentrations  of  HPC  to  felodipine-PEG   4000  binary  systems  to  
investigate the effect of hydrophilic polymer on the solubility and dissolution rate of 
the felodipine.  
 Chapter 1 discusses about the drug solubility and various approaches to 
improve the solubility especially on solid dispersions technology. Then, this chapter 
presents   the   method   of   preparation   of   solid   dispersion   systems   and   their  
characterization. Later part of this chapter provides the aims, objectives and plan of 
investigation of the study.  
 Chapter 2 deals with the literature review related to the past research 
work on solid dispersions and various carriers used to prepare solid dispersions.  
 Chapter 3  discusses  about  materials  used,  analytical  and  experimental 
methods employed in the present investigation. The first part of this chapter provides 
drug profile and polymer profile. Then later part of this chapter describes the method 
of preparation of solid binary systems of felodipine with PEG 4000 by kneading and 
solvent deposition method at different drug:carrier ratios of 1:1, 1:3 and 1:5 w/w. 
Then ternary systems were prepared by kneading method with addition of different 
concentrations of HPC (5%, 10% and 15%) to felodipine-PEG 4000 (1:3 ratio). The 
preceding part of this chapter deals with the methods of characterization of prepared 
solid binary and ternary systems by drug content uniformity, FT-IR, XRD and in 
vitro dissolution studies.  
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 Chapter 4 summarized all the research results of prepared solid binary 
and ternary systems of felodipine according to plan of investigations as described in  
 Chapter 5 provides the discussions on research results of solid binary and 
ternary systems of felodipine. All prepared solid binary and ternary systems were 
found  to  be  fine  and  free  flowing.  Solubility  studies  showed  that  the  solubility  of  
felodipine in different concentration of PEG 4000 increased linearly as a function of 
concentration of carrier. Low standard deviation (SD) values indicated uniform drug 
distribution in all prepared batches. The percentage yield of all formulations was 
found to be satisfactory. FT-IR studies indicated the possibility of intermolecular 
hydrogen bonding between amide group of the felodipine and hydroxyl group of the 
PEG 4000. XRD results of all solid binary and ternary systems indicated significant 
reduction in the felodipine crystallinity.  
 The results of the dissolution rate studies indicated higher dissolution rate 
of felodipine  from  solid  binary  systems  compared  to  felodipine  alone  and  their 
corresponding PMs. The DE30 and DE60 values of the solid binary systems prepared 
by kneading and solvent deposition methods were relatively high compared to the 
values  from the  PMs and  felodipine  alone.  The  value  of  T50 and  MDT of  all  solid  
binary systems were lower than felodipine alone. Further, it was found that the drug 
dissolution was higher in 1:5 drug to carrier ratio compared to 1:1 and 1:3 ratios. 
The overall the rank order of improvement in dissolution properties of felodipine 
with different methods in all ratios was found in the following rank order,  
 KM > SD > PMs > Felodipine 
 The DE30 and  DE60 values of the solid binary systems prepared by 
kneading method were higher compared to solid binary systems prepared by solvent 
deposition methods.  
 All  ternary  systems  prepared  with  different  concentrations  of  HPC  
exhibited a significant increase in dissolution rate with respect to the PMs and the 
felodipine  alone.   It   was   noted   that   the   dissolution   rate   was   progressively   
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increased  with increasing concentration of HPC in the ternary systems. Ternary 
system prepared with HPC 15% showed the most significant effect on the 
dissolution properties of drug. The increase in dissolution rate with these systems 
were found in the following manner,  
 HPC 15% > HPC 10% > HPC 5% 
 The release pattern in felodipine, PMs and all solid binary and ternary 
systems were found to be first order (best fit model) compared to Hixson-Crowell’s 
cube root model. The DE30 values of PMs and all solid binary and ternary systems 
prepared kneading  and  solvent  deposition  methods  were  significantly  higher  
(P <  0.01) compared to the DE30 values of felodipine alone.  
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CONCLUSION 
The following conclusions were drawn from the present investigations;  
x Solubility studies showed that the solubility of felodipine increased linearly as 
a function of concentration of carrier (PEG 4000).  
x All prepared solid binary and ternary systems were found to be fine and free 
flowing. 
x Drug  content  of  solid  binary (felodipine:PEG 4000)  and  ternary  systems 
(felodipine:PEG 4000:HPC) was uniform as indicated by the low SD (i.e., < 1) 
values. 
x The  FT-IR  studies  of  binary  and  ternary  systems  indicated  the  possibility  of  
intermolecular  hydrogen  bonding  between  amide  group  of  felodipine  and  
the hydroxyl group of the PEG 4000. 
x The XRD results of all solid binary and ternary systems indicated significant 
reduction in the felodipine crystallinity. 
x The in vitro dissolution studies indicated higher dissolution rate of felodipine 
from solid  binary  and  ternary  systems  compared  to  felodipine  alone  and  
the corresponding PMs.  
x The DE30 and DE60 values of the all solid binary systems prepared by kneading 
and solvent deposition methods were relatively high compared to the values 
from PMs  and felodipine alone.  
x The drug dissolution was higher in solid binary systems prepared by kneading 
and solvent deposition methods at 1:5 drug to carrier ratio compared to 1:1 and 
1:3 ratios. 
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x Comparatively, DE30 and DE60 values of the solid binary systems prepared by 
kneading  method  were  higher  compared  to solid binary systems  prepared  
by solvent deposition methods.  
x Ternary  systems  exhibited  a  progressive  increase  in  dissolution  rate  with  
increasing concentration of HPC. Ternary systems with HPC  15% showed the 
most significant effect on the dissolution properties of drug.  
x The release pattern in felodipine, PMs and all solid binary and ternary systems 
were found to be first order compared to Hixson-Crowell’s cube root model.  
x One-way ANOVA was used to analyse significant differences in the means of 
DE30 values felodipine, PMs and all solid binary and ternary systems. The 
DE30 values of PMs and all solid binary and ternary systems prepared by 
kneading and solvent deposition methods were significantly higher (P < 0.01) 
compared to the DE30 values of felodipine alone.  
x The overall results showed that dissolution rate of felodipine were 
considerably  improved when formulated in solid binary and ternary systems.  
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